NewzIntel.com

    • Checkout Page
    • Contact Us
    • Default Redirect Page
    • Frontpage
    • Home-2
    • Home-3
    • Lost Password
    • Member Login
    • Member LogOut
    • Member TOS Page
    • My Account
    • NewzIntel Alert Control-Panel
    • NewzIntel Latest Reports
    • Post Views Counter
    • Privacy Policy
    • Public Individual Page
    • Register
    • Subscription Plan
    • Thank You Page

Category: Business

  • MIL-OSI: Form 8.3 – [GLOBALDATA PLC – 07 05 2025] – (CGWL)

    Source: GlobeNewswire (MIL-OSI)

    FORM 8.3

    PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
    A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
    Rule 8.3 of the Takeover Code (the “Code”)

    1.        KEY INFORMATION

    (a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)
    (b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
            The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
    N/A
    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
            Use a separate form for each offeror/offeree
    GLOBALDATA PLC
    (d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
    (e)   Date position held/dealing undertaken:
            For an opening position disclosure, state the latest practicable date prior to the disclosure
    07 MAY 2025
    (f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
            If it is a cash offer or possible cash offer, state “N/A”
    N/A

    2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

    If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

    (a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

    Class of relevant security: 0.01p ORDINARY
      Interests Short positions
    Number % Number %
    (1)   Relevant securities owned and/or controlled: 11,102,260 1.3765    
    (2)   Cash-settled derivatives:        
    (3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
    TOTAL: 11,102,260 1.3765    

    All interests and all short positions should be disclosed.

    Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

    (b)      Rights to subscribe for new securities (including directors’ and other employee options)

    Class of relevant security in relation to which subscription right exists:  
    Details, including nature of the rights concerned and relevant percentages:  

    3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

    Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

    The currency of all prices and other monetary amounts should be stated.

    (a)        Purchases and sales

    Class of relevant security Purchase/sale Number of securities Price per unit
    0.01p ORDINARY PURCHASE 5,450 183.25p
    0.01p ORDINARY PURCHASE 11,000 183.75p

    (b)        Cash-settled derivative transactions

    Class of relevant security Product description
    e.g. CFD
    Nature of dealing
    e.g. opening/closing a long/short position, increasing/reducing a long/short position
    Number of reference securities Price per unit
    NONE        

    (c)        Stock-settled derivative transactions (including options)

    (i)        Writing, selling, purchasing or varying

    Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
    e.g. American, European etc.
    Expiry date Option money paid/ received per unit
    NONE              

    (ii)        Exercise

    Class of relevant security Product description
    e.g. call option
    Exercising/ exercised against Number of securities Exercise price per unit

    (d)        Other dealings (including subscribing for new securities)

    Class of relevant security Nature of dealing
    e.g. subscription, conversion
    Details Price per unit (if applicable)
    NONE      

    4.        OTHER INFORMATION

    (a)        Indemnity and other dealing arrangements

    Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
    Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

    NONE

    (b)        Agreements, arrangements or understandings relating to options or derivatives

    Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
    (i)   the voting rights of any relevant securities under any option; or
    (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
    If there are no such agreements, arrangements or understandings, state “none”

    NONE

    (c)        Attachments

    Is a Supplemental Form 8 (Open Positions) attached? NO
    Date of disclosure: 08 MAY 2025
    Contact name: MARK ELLIOTT
    Telephone number: 01253 376539

    Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

    The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

    The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Aemetis Reports First Quarter 2025 Financial Results

    Source: GlobeNewswire (MIL-OSI)

    • California Ethanol passes $2 billion cumulative revenue milestone.
    • Aemetis Biogas increased sales by 10,100 MMBtu compared with same quarter last year
    • Sales of investment tax credits resulted in cash proceeds of $19.0 million during Q1 2025.
    • India Biodiesel received letters of intent in April for an aggregate of $31 million of biodiesel sales to OMCs for delivery in May, June and July of 2025.

    CUPERTINO, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products that replace petroleum products and reduce greenhouse gas emissions, today announced its financial results for the three months ended March 31, 2025.

    “Revenues during the first quarter of 2025 of $42.9 million reflect continued and strong execution by our California Ethanol and Dairy Renewable Natural Gas segments. After a pause in production and supply under the OMC contracts, our India Biodiesel segment is now approved to return to regular production levels,” said Todd Waltz, Chief Financial Officer of Aemetis. “We look forward to substantial additional revenues when we receive the LCFS provisional pathway approvals that are expected to approximately double our LCFS revenues and receive the federal Inflation Reduction Act Section 45Z production tax credits,” added Waltz.

    “We are pleased with the continued growth of Aemetis Biogas production and continued progress with building a large centralized dairy digester to process waste from four dairies that is expected to be operational in the next few months,” said Eric McAfee, Chairman and CEO of Aemetis. “Our continued focus on significantly improving cash flow from our California Ethanol segment by replacing fossil natural gas with lower carbon electricity is now underway with the fabrication of the equipment for the mechanical vapor recompression project.”

    Today, Aemetis will host an earnings review call at 11:00 a.m. Pacific time (PT).

    Live Participant Dial In (Toll Free): +1-877-545-0523 entry code 761021
    Live Participant Dial In (International): +1-973-528-0016 entry code 761021
    Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/52416

    For details on the call, please visit http://www.aemetis.com/investors/conference-calls/

    Financial Results for the Three Months Ended March 31, 2025

    Total revenues during the first quarter of 2025 were $42.9 million compared to $72.6 million for the first quarter of 2024. Delays with the receipt of contracts in India from the government-owned Oil Marketing Companies accounted for the decline in revenue. New OMC letters of intent for $31 million were issued in April 2025 and we started shipments in April. Our Keyes ethanol plant increased revenues by $1.7 million due principally to an increase in the average price of Ethanol from $1.79 during 2024 to $1.98 during the first quarter of 2025. Our Dairy Natural Gas segment sold 70,900 MMBtu of renewable natural gas, an increase of 10,100 MMBtu from the same quarter last year.

    Gross loss for the first quarter of 2025 was $5.1 million, compared to a $0.6 million loss during the first quarter of 2024.

    Selling, general and administrative expenses increased by $1.6 million to $10.5 million during the first quarter of 2025 compared to $8.9 million during the same period in 2024, driven primarily from legal and other transaction costs associated with receiving $18 million of cash proceeds from tax credit sales during the first quarter.

    Operating loss was $15.6 million for the first quarter of 2025, compared to operating loss of $9.5 million for the same period in 2024.

    Interest expense, excluding accretion of Series A preferred units in the Aemetis Biogas LLC subsidiary, increased to $13.7 million during the first quarter of 2025 compared to $10.5 million during the first quarter of 2024. Additionally, Aemetis Biogas recognized $2.3 million of accretion of Series A preferred units during the first quarter of 2025 compared to $3.3 million during the first quarter of 2024.

    Income tax expense included a benefit from the sale of $7.0 million of Investment Tax Credits during the first quarter of 2025.

    Net loss was $24.5 million for the first quarter of 2025, compared to net loss of $24.2 million for the first quarter of 2024.

    Cash at the end of the first quarter of 2025 was $500 thousand compared to $900 thousand at the close of the fourth quarter of 2024. We recorded investments in capital projects related to the reduction of the carbon intensity of Aemetis ethanol and construction of dairy digesters of $1.8 million for the first quarter of 2025. Additionally, payments of $15.4 million were applied to the repayment of debt during the first quarter.

    About Aemetis

    Headquartered in Cupertino, California, Aemetis is a renewable natural gas and renewable fuel company focused on the operation, acquisition, development, and commercialization of innovative technologies that replace petroleum products and reduce greenhouse gas emissions. Founded in 2006, Aemetis is operating and actively expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis owns and operates an 80 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin. Aemetis is developing a sustainable aviation fuel and renewable diesel fuel biorefinery in California, renewable hydrogen, and hydroelectric power to produce low carbon intensity renewable jet and diesel fuel. For additional information about Aemetis, please visit www.aemetis.com. 

    Company Investor Relations
    Media Contact:
    Todd Waltz
    (408) 213-0940
    investors@aemetis.com

    External Investor Relations
    Contact:
    Kirin Smith
    PCG Advisory Group
    (646) 863-6519
    ksmith@pcgadvisory.com

    NON-GAAP FINANCIAL INFORMATION

    We have provided non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data. Adjusted EBITDA is defined as net income/(loss) plus (to the extent deducted in calculating such net income) interest and amortization expense, income tax expense or benefit, accretion expense, depreciation expense, and share-based compensation expense.

    Adjusted EBITDA is not calculated in accordance with GAAP and should not be considered as an alternative to net income/(loss), operating income or any other performance measures derived in accordance with GAAP or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA is presented solely as a supplemental disclosure because management believes that it is a useful performance measure that is widely used within the industry in which we operate. In addition, management uses Adjusted EBITDA for reviewing financial results and for budgeting and planning purposes. EBITDA measures are not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure for comparison.

    Safe Harbor Statement

    This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to our five-year growth plan; trends in market conditions with respect to prices for inputs for our products versus prices for our products; our ability to fund, develop, build, maintain and operate digesters, facilities and pipelines for our Dairy Renewable Natural Gas segment; our ability to fund, develop and operate our Sustainable Aviation Fuel, Renewable Diesel, and Carbon Capture and Sequestration projects, including obtaining required permits; our ability to receive awarded grants by meeting all of the required conditions, including meeting the minimum contributions; our ability to fund, develop and operate our sustainable aviation fuel and renewable biodiesel projects; our intention to repurchase the Series A preferred units relating to our Aemetis Biogas subsidiary and the expected valuation premium thereof; and our ability to raise additional capital. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “view,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other filed documents. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

    (Tables follow)

    AEMETIS, INC.  
    CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS  
    (unaudited, in thousands, except per share data)  
                   
            For the three months ended March 31,  
              2025       2024    
                   
    Revenues   $ 42,886     $ 72,634    
    Cost of goods sold     47,966       73,246    
    Gross loss     (5,080 )     (612 )  
                   
    Selling, general and administrative expenses     10,475       8,850    
    Operating loss     (15,555 )     (9,462 )  
                   
    Other expense (income):          
      Interest expense          
        Interest rate expense     11,018       9,092    
        Debt related fees and amortization expense   2,675       1,421    
        Accretion and other expenses of Series A preferred units   2,279       3,311    
      Other (income) expense     (215 )     67    
    Loss before income taxes     (31,312 )     (23,353 )  
      Income tax expense (benefit)     (6,783 )     878    
    Net loss   $ (24,529 )   $ (24,231 )  
                   
    Net loss per common share          
      Basic   $ (0.47 )   $ (0.58 )  
      Diluted   $ (0.47 )   $ (0.58 )  
                   
    Weighted average shares outstanding          
      Basic     52,584       41,889    
      Diluted     52,584       41,889    
                   
             
    AEMETIS, INC.
    CONSOLIDATED CONDENSED BALANCE SHEETS
    (in thousands)
                     
              March 31, 2025   December 31, 2024  
              (Unaudited)      
    Assets              
      Current assets:            
        Cash and cash equivalents     $ 499     $ 898    
        Accounts receivable     1,043       1,805    
        Inventories       22,930       25,442    
        Tax credit sale receivable       –       12,300    
        Prepaid and other current assets       4,021       4,251    
      Total current assets       28,493       44,696    
                     
        Property, plant and equipment, net       199,435       199,392    
        Other assets       14,590       15,214    
      Total assets     $ 242,518     $ 259,302    
                     
    Liabilities and stockholders’ deficit            
      Current liabilities:            
        Accounts payable     $ 32,115     $ 33,139    
        Current portion of long term debt       93,669       63,745    
        Short term borrowings     25,878       26,789    
        Other current liabilities       22,939       20,295    
      Total current liabilities       174,601       143,968    
                     
      Total long term liabilities       348,612       379,262    
                     
      Stockholders’ deficit:            
        Common stock     54       51    
        Additional paid-in capital       313,075       305,329    
        Accumulated deficit     (587,471 )     (562,942 )  
        Accumulated other comprehensive loss       (6,353 )     (6,366 )  
      Total stockholders’ deficit       (280,695 )     (263,928 )  
    Total liabilities and stockholders’ deficit     $ 242,518     $ 259,302    
                 
                     
    AEMETIS, INC.
    RECONCILIATION OF ADJUSTED EBITDA TO NET INCOME/(LOSS)
    (unaudited, in thousands)
                 
                 
          For the three months ended March 31,  
      EBITDA Calculation   2025       2024    
                 
      Net income (loss) $ (24,529 )   $ (24,231 )  
      Adjustments        
        Interest and amortization expense   13,705       10,525    
        Depreciation expense   2,357       1,798    
        Accretion of Series A preferred units   2,279       3,311    
        Share-based compensation   2,308       2,969    
        Income tax expense (benefit)   (6,783 )     878    
      Total adjustments   13,866       19,481    
                 
      Adjusted EBITDA $ (10,663 )   $ (4,750 )  
                 
                 
    AEMETIS, INC.
    PRODUCTION AND PRICE PERFORMANCE
    (unaudited)
               
      Three Months ended March 31,  
        2025       2024    
               
    California Ethanol          
    Ethanol          
    Gallons sold (in millions)   14.1       14.1    
    Average sales price/gallon $ 1.98     $ 1.79    
    Percent of nameplate capacity   103 %     103 %  
    WDG          
    Tons sold (in thousands)   93       94    
    Average sales price/ton $ 86     $ 98    
    Delivered Cost of Corn          
    Bushels ground (in millions)   4.8       4.9    
    Average delivered cost / bushel $ 6.63     $ 6.33    
               
    California Dairy Renewable Natural Gas          
    Renewable Natural Gas          
    MMBtu sold (in thousands)   70.9       60.8    
    Average price per MMBtu $ 3.65     $ 4.02    
    MMBtu stored as inventory   33.1       46.8    
    RINs          
    RINs sold (in thousands)   388.2       766.4    
    Average price per RIN $ 2.64     $ 3.08    
    LCFS          
    LCFS credits sold (in thousands)   16.0       18.0    
    Average price per LCFS credit $ 72.50     $ 66.00    
               
    India Biodiesel          
    Biodiesel          
    Metric tons sold (in thousands)   0       27.5    
    Average Sales Price/Metric ton $ –     $ 1,127    
    Percent of Nameplate Capacity   0 %     73.4 %  
    Refined Glycerin          
    Metric tons sold (in thousands)   0.0       2.4    
    Average Sales Price/Metric ton $ –     $ 551    

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Xunlei Limited Schedules 2025 Unaudited First Quarter Earnings Release on May 15, 2025

    Source: GlobeNewswire (MIL-OSI)

    SHENZHEN, China, May 08, 2025 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading technology company providing distributed cloud services in China, today announced that it plans to release its unaudited financial results for the first quarter ended March 31, 2025 on May 15, 2025 before market open.

    The earnings press release will be available on the Company’s investor relations page at http://ir.xunlei.com.

    Conference Call

    Xunlei’s management will host a conference call at 8:00 a.m. U.S. Eastern Time on May 15, 2025 (8:00 p.m. Beijing/Hong Kong Time), to discuss the Company’s quarterly results and recent business developments.

    Conference Call Preregistration

    Participant Online Registration:
    https://register-conf.media-server.com/register/BIe31316b11951413ca6026dd0a7227b38

    Please register to join the conference using the link provided above and dial in 10 minutes before the call is scheduled to begin. Once registered, the participants will receive an email with personal PIN and dial-in information, and participants can choose to access either via Dial-In or Call Me. A kindly reminder that “Call Me” does not work for China number.

    The Company will also broadcast a live audio webcast of the conference call. The webcast will be available at http://ir.xunlei.com. Following the earnings conference call, an archive of the call will be available at https://edge.media-server.com/mmc/p/vrett8r2

    About Xunlei

    Founded in 2003, Xunlei Limited (NASDAQ: XNET) is a leading technology company providing distributed cloud services in China. Xunlei provides a wide range of products and services across cloud acceleration, shared cloud computing and digital entertainment to deliver an efficient, smart and safe internet experience.

    Contact:
    Xunlei Limited Investor Relations

    Email: ir@xunlei.com
    Tel: +86 755 6111 1571
    Website: http://ir.xunlei.com

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Scality named a 2025 Stevie Award winner

    Source: GlobeNewswire (MIL-OSI)

    SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) — Scality, a global leader in cyber-resilient storage software for the AI era, announced today that its ARTESCA 3.0 solution earned a Gold Stevie® Award in the Cloud Storage & Backup Solution category, the highest award level, as part of The 23rd Annual American Business Awards®.

    The American Business Awards — a.k.a. “The Stevies” — is a premier business awards program in the US. All organizations operating in the country are eligible to submit nominations – public and private, for-profit and nonprofit, large and small.

    Launched nearly a year ago, ARTESCA 3.0 introduced groundbreaking CORE5 API-to-Architecture cyber resilience. CORE5 is a reference to the five levels of ransomware protection: 1) API, 2) data, 3) storage, 4) geography, and 5) architecture. ARTESCA 3.0 is the first object storage solution of any kind to offer such a comprehensive level of protection.

    Since then, the company has released an all-flash version of the ARTESCA hardware appliance and a pay-as-you-go service offering for Veeam cloud service providers. Last week, Scality unveiled another industry first: the ARTESCA+ Veeam unified software appliance, which combines Veeam Backup & Replication™ software with ARTESCA object storage software in a single, streamlined software appliance.

    With a variety of deployment models, ARTESCA provides midsize enterprises and companies that lack deep technical resources enterprise-grade cyber-resilient storage without the need for deep storage or OS expertise. ARTESCA has become a critical offering — and a cash cow — for channel partners, who have found that the product uniquely meets the needs of this customer segment.

    “Where the industry had previously been focused on immutability, ARTESCA raised the bar significantly over the past year with its five-level end-to-end cyber resilience,” said Eric LeBlanc, GM, ARTESCA and Channel Chief, Scality. “Its fast deployment and easy maintenance has put industry-standard cybersecurity within the reach of smaller companies, which is why ARTESCA continues to garner recognition from independent third parties.”

    Nicknamed the Stevies for the Greek word meaning “crowned,” The American Business Awards garnered more than 3,600 nominations from organizations of all sizes and in virtually every industry across a wide range of categories. More than 250 professionals worldwide participated in the judging process to select this year’s Stevie Award winners.

    “Organizations across the United States continue to demonstrate resilience and innovation,” said Stevie Awards president Maggie Miller. “The 2025 Stevie winners have helped drive that success through their innovation, persistence, and hard work. We congratulate all of the winners in the 2025 ABAs and look forward to celebrating their achievements during our June 10 gala event in New York.”

    Details about The American Business Awards and the list of 2025 Stevie winners are available at www.StevieAwards.com/ABA. For more information about ARTESCA, visit the product line’s microsite.

    About the Stevie Awards
    Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Sales & Customer Service, and the Stevie Awards for Technology Excellence. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com. 

    About Scality
    Scality solves organizations’ biggest data storage challenges — growth, security, performance, and cost. Designed for end-to-end cyber resilience, only Scality S3 object storage with CORE5 safeguards data at every level of the system, from API to architecture. Its patented MultiScale Architecture enables limitless, independent scalability in all critical dimensions to meet the unpredictable demands of modern workloads. The world’s most discerning companies depend on Scality to accelerate high-performance AI initiatives, optimize cloud deployments, and defend their data with confidence. Recognized as a leader by Gartner, Scality software is reliable, secure, and sustainable. Follow us on LinkedIn. Visit www.scality.com and our blog.

    Media Contact:
    Jon Lavietes
    A3 Communications
    +1 415-572-4408
    jon.lavietes@a3communicationspr.com

    Photos accompanying this announcement are available at

    https://www.globenewswire.com/NewsRoom/AttachmentNg/92069d27-1be4-4653-aed9-6dca964cb48f

    https://www.globenewswire.com/NewsRoom/AttachmentNg/3a34a1c9-36f3-4c09-b2c6-eb46f902fdb7

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Infinidat Wins 2025 Global InfoSec Awards for Cyber Resilience, Cyber Storage, and Ransomware Recovery from Cyber Defense Magazine

    Source: GlobeNewswire (MIL-OSI)

    WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) — Infinidat, a leading provider of enterprise storage solutions, today announced that the company has won three Global InfoSec Awards from Cyber Defense Magazine, a leading information security magazine. The 2025 awards for Infinidat include “Hot Company – Cyber Resilience,” “Hot Company – Cyberstorage” and “Editor’s Choice – Ransomware Recovery.” This is Cyber Defense Magazine’s 13th year of honoring InfoSec innovators around the world.

    “Infinidat offers the most comprehensive cyber resilience and cyber recovery solutions for enterprise storage on the market today. This includes our all-inclusive award-winning InfiniSafe solutions for automated cyber protection, cyber detection, and all the essential cyber storage resilience and recovery capabilities,” said Eric Herzog, CMO at Infinidat. “We’re pleased to be recognized as a ‘Hot Company’ for cyber resilience and cyber storage and to win ‘Editor’s Choice’ for ransomware recovery. Infinidat’s next-generation data protection strategy has pioneered a cyber-focused, recovery-first approach, significantly reducing the impact of cyberattacks. Infinidat injects cyber resilience and cyber recovery into the critical parts of an enterprise data infrastructure and guarantees – yes, guarantees − recovery of data within minutes.”

    Cyber resilience and cyber recovery are crucial for modern enterprise data infrastructure. It is no longer a question of “if” your enterprise will suffer a cyberattack, but “when” and “how often.” Enterprise storage systems must be fortified against cyberattacks that corrupt, ensnare or steal business-critical data. Cybersecurity can no longer simply rely on securing the perimeter; it’s critical that the enterprise storage infrastructure itself is secured from within. Traditional systems have become weak points for attacks. Infinidat’s cyber storage solutions are designed to provide a robust defense against cyberattacks – especially ransomware and malware – enabling swift recovery and business continuity in the wake of an incident.

    As a leader in enterprise storage cyber resilient and cyber recovery solutions, Infinidat first unveiled its InfiniSafe® software-based platform three years ago with a set of cybersecurity functions. The comprehensive cyber resilience and recovery capabilities of InfiniSafe dramatically improve the ability of an enterprise to combat and protect against ever-increasing cyberattacks and data breaches by uniquely combining immutable snapshots, logical air gapping, a fenced forensic environment, the ability to seamlessly integrate with data center-wide cyber security software or an enterprise’s Security Operations Center (SOC), virtually instantaneous data recovery, and the capability of using AI and ML technology to scan storage for cyberattacks into a single, high-performance platform.

    Gary S. Miliefsky, Publisher of Cyber Defense Magazine, said, “Infinidat embodies three major features we judges look for to become winners: understanding tomorrow’s threats, today, providing a cost-effective solution and innovating in unexpected ways that can help mitigate cyber risk and get one step ahead of the next breach.”

    The judges for the Global Infosec Awards are CISSP, FMDHS, CEH, certified security professionals who voted based on their independent review of the company submitted materials on the website of each submission, including but not limited to data sheets, white papers, product literature and other market variables. Cyber Defense Magazine has a flexible philosophy to find more innovative players with new and unique technologies. Cyber Defense Magazine specializes in identifying best-of-breed, next-generation information security solutions.

    About Cyber Defense Magazine
    Cyber Defense Magazine is the premier source of cyber security news and information for InfoSec professions in business and government. Its mission is to share cutting-edge knowledge, real-world stories and awards on the best ideas, products, and services in the information technology industry. It delivers electronic magazines every month online for free, and special editions exclusively for the RSA Conferences. CDM is a proud member of the Cyber Defense Media Group. Learn more at https://www.cyberdefensemagazine.com.

    About Infinidat
    Infinidat provides enterprises and service providers with a platform-native primary and secondary storage architecture that delivers comprehensive data services based on InfiniVerse®. This unique platform delivers outstanding IT operating benefits, support for modern workloads across on-premises and hybrid multi-cloud environments. Infinidat’s cyber resilient-by-design infrastructure, consumption-based performance, 100% availability, and cyber security guaranteed SLAs align with enterprise IT and business priorities. Infinidat’s award-winning platform-native data services and acclaimed white glove service are continuously recommended by customers. For more information, visit www.infinidat.com.

    Connect with Infinidat
    About Infinidat
    Read our blog
    Follow us on X
    Join us on LinkedIn
    Visit us on Facebook
    See us on YouTube
    Be our partner

    Media Contact
    Infinidat
    Sapna Capoor
    Director of Global Communications
    scapoor@infinidat.com I Mobile: +44 (0) 7789684159

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Live Oak Bancshares Announces Appointment of Patrick T. McHenry to Board of Directors

    Source: GlobeNewswire (MIL-OSI)

    WILMINGTON, N.C., May 08, 2025 (GLOBE NEWSWIRE) — Live Oak Bancshares announced the appointment of Patrick T. McHenry to its board of directors effective May 21, 2025. McHenry has also been appointed to the board of directors of Live Oak Bank.

    “It is a privilege for Live Oak to have the astute financial and policy expertise of Patrick’s caliber join our board of directors,” said Live Oak Bancshares Chairman and CEO James S. (Chip) Mahan III. “His service to the U.S. government, and experience as former chairman of the House Financial Services Committee, will be a valuable addition to our leadership as Live Oak continues its mission to be America’s small business bank.”

    McHenry currently lives in Washington, D.C. and serves as an advisor on public policy, financial services, fintech, and artificial intelligence matters, in addition to serving as a distinguished fellow at Georgetown University’s Psaros Center for Financial Markets and Policy. He spent 20 years in Congress and is the former Chairman of the House Financial Services Committee and U.S. Representative for North Carolina’s 10th Congressional District. During his time leading the committee, McHenry drove a robust legislative agenda focused on cryptocurrency, capital formation, AI, fintech, data privacy, and corporate governance issues, among other topics.

    “Small business is a critical component of the U.S. economy, and I have long respected Live Oak Bank’s approach to supporting the capital needs of American entrepreneurs,” said McHenry. “There is a unique culture at Live Oak–one driven by an embrace of innovation and technology, two things that inspired much of my public policy work over the last 20 years. I am delighted to be part of the journey Chip and the team are on to serve small businesses in my home state of North Carolina and around the country.”

    In addition to his role as Chairman of the Financial Services Committee, McHenry previously served in House Republican leadership as the Chief Deputy Whip and also served as Speaker Pro Tempore of the House in October of 2023. He is a native of Gastonia, NC and a graduate of Belmont Abbey College.

    About Live Oak Bancshares
    Live Oak Bancshares, Inc. (NYSE: LOB) is a financial holding company and parent company of Live Oak Bank. Live Oak Bancshares and its subsidiaries partner with businesses who share a groundbreaking focus on service and technology to redefine banking. To learn more, visit www.liveoak.bank.

    Contact:
    Claire Parker
    Live Oak Bank, Corporate Communications
    910.597.1592
    claire.parker@liveoak.bank

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Angry Shrimp Media Now ‘Go-To’ Growth Engine Builder for Founders and CEOs Scaling Smarter

    Source: GlobeNewswire (MIL-OSI)

    Cape Coral, Florida, May 08, 2025 (GLOBE NEWSWIRE) — Angry Shrimp Media is redefining what smart scale looks like for today’s B2B leaders. Built for SaaS founders & CEOs, VC portfolio companies, and legacy brand owners tired of bloated ads budgets & inefficient funnels; Angry Shrimp delivers lean, high-performing growth systems that actually convert. With customer acquisition costs rising and performance pressure mounting, their proven frameworks are helping Founders and CEOs plug revenue leaks, automate sales pipelines, and scale profitably—without adding unnecessary headcount or overhead. 

    Angry Shrimp Media

    Working at the intersection of marketing automation, strategic business development, and high-ticket sales enablement, Angry Shrimp Media tailors solutions to each client’s customer journey to deliver higher conversion rates and lower customer acquisition costs (CAC). By identifying funnel leaks and building scalable growth architecture, the firm accelerates market adoption while providing companies with predictable revenue paths.

    “At Angry Shrimp Media, we believe that sustainable growth comes from aligning sales, marketing, and operations through intelligent, scalable systems—not guesswork,” said Mandy Gartrell, Founder and CEO. “Our mission is to empower brands to break through their growth ceilings with proven frameworks that blend automation, AI, and strategic insight.”

    Gartrell, a marketing and sales powerhouse with over 16 years of hands-on industry experience; leads a team focused on performance-driven results, not extra costs. The firm’s flexible engagement models—including flat-fee projects, strategic retainers, and revenue-share partnerships—make it an attractive growth partner for companies seeking fast, efficient scale without the burden of expanding internal teams.

    Growth Solutions for a New Era & Leaders Who Want Results

    Angry Shrimp Media’s services are specifically designed for high-growth companies facing challenges in scaling revenue effectively. The firm’s offerings include:

    • Strategic funnel audits and conversion optimization
    • Market Adoption, Architecture, and AI-powered business scaling
    • Full-funnel buildouts and conversion tracking
    • B2B SaaS and legacy brand transformation initiatives
    • Marketing automation systems customized for scalable, repeatable success that also frees up teams and improves efficiency
    • Executive partnership models for CEOs needing senior-level growth strategy without full-time hires
    •  Executive & Founder Growth Leadership Coaching
    • Strategic go-to-market consulting for venture capital backed and legacy businesses

    Angry Shrimp’s impact speaks for itself:

    • A B2B SaaS company saw a 33% increase in qualified leads and a 25% jump in demo-to-close rates after a full-funnel audit and targeted optimization.
    • A PE-backed legacy brand achieved 22% revenue growth in 6 months by implementing a streamlined sales pipeline and automated nurture systems, cutting CAC by 15%.
    • A DTC eCommerce brand scaled to 7-figure revenue while maintaining lean internal operations, thanks to a growth architecture built for efficiency and repeatability.

    By combining AI integration with decades of strategic growth experience, Angry Shrimp Media positions itself as a new kind of partner—one capable of delivering the velocity and precision that today’s competitive market demands.

    About Angry Shrimp Media

    Angry Shrimp Media is a revenue-focused growth consultancy co-founded by Mandy Gartrell, a seasoned Growth Architect and Fractional CMO, and Ryan Gartrell, a sought-after Revenue Operations strategist with over two decades of experience optimizing operational systems and scaling performance. The firm partners with high-growth B2B SaaS companies, venture-backed portfolios, and legacy business owners to engineer smarter scale—driving sustainable revenue through funnel optimization, scalable growth architecture, and sales enablement systems. With a bold name and an even bolder approach, Angry Shrimp Media is the force behind some of today’s most compelling B2B growth stories.

    Learn more at https://angryshrimp.com.

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Zscaler to Host Third Quarter Fiscal Year 2025 Earnings Conference Call

    Source: GlobeNewswire (MIL-OSI)

    SAN JOSE, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, will release third quarter fiscal year 2025 earnings after the market closes on Thursday, May 29, 2025. The company will host an investor conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.

    Date: Thursday, May 29, 2025
    Time: 1:30 p.m. PT
    Webcast: https://ir.zscaler.com
    Dial-in: To join by phone, register at the following link: Click Here. After registering, you will be provided with a dial-in number and a personal PIN that you will need to join the call.

    Please dial in at least 10 minutes prior to the 1:30 p.m. PT start time. A live webcast of the conference call will be accessible from the Zscaler website at ir.zscaler.com. Listeners may log on to the call under the “Events & Presentations” section and select “Q3 2025 Zscaler Earnings Conference Call” to participate.

    About Zscaler

    Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange™ platform protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across more than 150 data centers globally, the SASE-based Zero Trust Exchange™ is the world’s largest in-line cloud security platform.

    Zscaler™ and the other trademarks listed at https://www.zscaler.com/legal/trademarks are either (i) registered trademarks or service marks or (ii) trademarks or service marks of Zscaler, Inc. in the United States and/or other countries. Any other trademarks are the properties of their respective owners.

    Media Relations Contact:
    Pavel Radda
    press@zscaler.com

    Investor Relations Contact:
    Ashwin Kesireddy
    ir@zscaler.com

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Enphase Energy Announces Easy Expansion of IQ7 Solar Systems with IQ8 Microinverters

    Source: GlobeNewswire (MIL-OSI)

    FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced the availability of new software that allows homeowners with existing legacy IQ7™ Microinverter-based systems to seamlessly expand their solar capacity using IQ8™ Microinverters. This software is now available across North America, Europe, and other key markets.

    With over one million homes worldwide using IQ7™ Microinverters, many homeowners are now looking to expand their systems to reduce energy costs and boost energy independence. Enphase’s new software enables solar installers to upgrade these systems with IQ8™ Microinverters, built for high-powered solar panels, while using the existing IQ® Gateway or IQ® Combiner hardware.

    “Enphase’s new expansion capability with the IQ8 Microinverters is a game-changer for us,” said Jeremy White, project manager at Robco Electric, an installer of Enphase products in the United States. “It allows us to offer our customers a straightforward path to scale their systems as their energy needs grow. We can now deliver more power with fewer headaches, which helps us provide the best service and keeps our business running efficiently.”

    “Homeowners are increasingly asking for ways to get more out of their existing systems, and the new IQ8 Microinverters make that possible,” said Mauricio Llovera, CEO of INVERSOL, an installer of Enphase products in Mexico. “This solution is a win-win, as it not only benefits our customers but also enables us to take on more projects without the complexity of traditional system upgrades. It’s the kind of innovation we’ve come to expect from Enphase.”

    “We’re excited to see Enphase continue to build on its existing product suite, constantly making our lives easier,” said David Monnier, CEO of La Maison des Energies, an installer of Enphase products in Switzerland. “The IQ8 Microinverters provide a seamless integration experience, allowing us to maximize energy output for our customers while maintaining the reliability and quality Enphase is known for. This capability is a significant boost to our business.”

    “The ability to upgrade existing IQ7 systems with IQ8 Microinverters opens up new opportunities for homeowners in the Netherlands,” said Jack van der Linden, account manager at Green Guys BV, an installer of Enphase products in the Netherlands. “With energy prices fluctuating, our customers want to optimize their solar systems without costly overhauls. This new solution from Enphase allows them to do just that — scaling their energy production efficiently and cost-effectively.”

    “Enphase’s latest innovation simplifies system upgrades for our customers in France, making it easier than ever to enhance solar production,” said Julien Vouriot, CEO and founder of Solair’ Forez, an installer of Enphase products in France. “We can now provide homeowners with a seamless way to integrate the latest microinverter technology, ensuring they get the most out of their solar investments while maintaining system reliability.”

    “The new software release unlocks seamless interoperability between IQ7 and IQ8 microinverters, which empowers our global installer network to deliver more value with less effort,” said Aaron Gordon, senior vice president and general manager of the systems business unit at Enphase Energy. “It’s a win for homeowners and a growth driver for our installers.”

    Enphase’s software-defined energy systems allow homeowners the ability to scale and optimize their solar investments over time. For more information about adding IQ8 Microinverters to IQ7 systems, watch the video here and visit the regional websites — United States, France, Switzerland, the Netherlands, and Germany.

    About Enphase Energy, Inc.

    Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s leading supplier of microinverter-based solar and battery systems that enable people to harness the sun to make, use, save, and sell their own power — and control it all with a smart mobile app. The company revolutionized the solar industry with its microinverter-based technology and builds all-in-one solar, battery, and software solutions. Enphase has shipped approximately 81.5 million microinverters, and approximately 4.8 million Enphase-based systems have been deployed in over 160 countries. For more information, visit https://enphase.com/.

    ©2025 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. in the U.S. and other countries. Other names are for informational purposes and may be trademarks of their respective owners.

    Forward-Looking Statements

    This press release may contain forward-looking statements, including statements related to the expected capabilities and performance of Enphase Energy’s technology and products, including safety, quality, and reliability; and the ability to continually enhance and maximize the value of their investments over the lifetime of the systems. These forward-looking statements are based on Enphase Energy’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties including those risks described in more detail in Enphase Energy’s most recently filed Quarterly Report on Form 10-Q, Annual Report on Form 10-K, and other documents filed by Enphase Energy from time to time with the SEC. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations, except as required by law.

    Contact:

    Enphase Energy

    press@enphaseenergy.com

    This press release was published by a CLEAR® Verified individual.

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Obra Capital Announces Promotion of Peter Polanskyj to Chief Investment Officer

    Source: GlobeNewswire (MIL-OSI)

    NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Obra Capital, Inc. (along with its affiliated registered investment advisors, collectively “Obra”), an asset management firm with a specialized approach to alternative investing, today announced that Peter Polanskyj, Senior Managing Director and Head of Structured Credit, has been promoted to Chief Investment Officer.

    Since joining Obra in 2022, Mr. Polanskyj has been a key member of the leadership team, supporting the guidance and execution of the firm’s growth strategy and the development of both its platform and enhanced product set. In April 2024, he supported the launch of Obra’s first ETFs, creating investment options with access to a wide variety of securitized products. In December 2024, Mr. Polanskyj helped lead a $400 million close of Obra’s inaugural Collateralized Loan Obligation offering (“CLO”), further diversifying the firm’s strategies in alternative assets and structured credit to provide a range of solutions aimed at delivering long-term value for investors.

    In addition to new product launches, Mr. Polanskyj has demonstrated a proven track record of prudent capital stewardship, leveraging over 28 years of experience investing in a variety of structured investments to achieve a net growth rate for Obra’s insurance special situations strategy that has outpaced the firm’s initial expectations. In his new role, he will chair Obra’s Investment Committee, with oversight of the firm’s operations across its portfolio.

    “I’m thrilled to welcome Peter to fill this role on Obra’s leadership team,” said Blair Wallace, President and Chief Executive Officer. “He has contributed to the rapid growth of our platform by adeptly navigating a nuanced area of the market, launching unique products and providing strong performance for our investors. His specialized experience and skillset will be critical as we look to build on our momentum across credit and insurance investment opportunities.”

    Mr. Polanskyj added, “I am proud of the work we have done developing the capabilities that our investors are looking to access across insurance and credit. As I step into this new role as CIO, I look forward to continuing to work with Blair and the team to develop our platform and deliver for investors.”

    In addition, Matt Roesler has been promoted to Senior Managing Director and Head of Multi-Sector Credit. He continues to lead the management of Obra’s multi-sector credit, liability-driven and other insurance portfolios. Greg Nicolls has been promoted to Senior Managing Director and Head of Business Development and Investor Relations.

    Prior to joining Obra, Mr. Polanskyj was a Managing Director and Head of U.S. CLO Management at Sculptor Capital (formerly known as Och-Ziff), where he oversaw the creation, securitization and management of CLOs and similarly structured products. In his time with the firm, he grew this business from inception in 2012 to approximately $15 billion in assets in 2022. Prior to that role, he worked at Morgan Stanley in a variety of capacities, including as a strategist focused on credit, structured credit, equity derivatives and capital structure arbitrage. Previously, Mr. Polanskyj was a reinsurance actuary with a focus on property and casualty. Mr. Polanskyj holds a Bachelor of Arts in Economics and Mathematics from Rutgers University, where he was named a Henry Rutgers scholar, and a Master of Business Administration from Columbia Business School.

    About Obra Capital

    Obra is a specialized alternative asset management firm with approximately $5.6 billion in capital under management as of March 31, 2025. Obra provides investment products and solutions across insurance, multi-sector credit, asset-based finance and longevity investment strategies. Obra aims to generate long-term value and attractive returns for investors through a variety of funds and separate accounts. With capabilities in investing, originating, structuring and servicing, Obra strives to provide differentiated investment opportunities and capital solutions for investors worldwide. Obra owns and operates a CLO management business, a commercial real estate lending platform and an auto finance company. For more information about Obra and its registered investment advisors, please visit www.obra.com.

    Media Contact:
    Dan Gagnier
    Gagnier Communications
    Obra@gagnierfc.com
    646-569-5897

    The MIL Network –

    May 9, 2025
  • MIL-OSI: BermudAir Partners with Zero Hash to Launch First-of-Its-Kind Stablecoin Payments in Air Travel

    Source: GlobeNewswire (MIL-OSI)

    HAMILTON, Bermuda, May 08, 2025 (GLOBE NEWSWIRE) — BermudAir, Bermuda’s first homegrown airline, today announced a groundbreaking partnership with Zero Hash to let customers purchase flights with stablecoins as part of the standard booking flow by the end of 2025. The new feature, which makes BermudAir the world’s first airline to offer native stablecoin payments for tickets during online booking on its website and mobile app, will go live by the end of 2025. The collaboration is being showcased today at the inaugural Bermuda Digital Finance Forum, underscoring the event’s focus on empowering local Bermudian businesses through cutting-edge digital finance innovation.

    This partnership will allow BermudAir passengers to natively pay with stablecoins – digital currencies pegged to fiat value – directly on the airline’s website, just as easily as using a credit card. Once live, travelers can select from over a dozen stablecoin options at checkout, enabling seamless payments that settle nearly instantly across borders.

    “By accepting stablecoins, we’re eliminating the friction of currency exchange and foreign transaction fees for our international passengers,” said Adam Scott, Founder and CEO of BermudAir. “As Bermuda’s home airline, we are proud to lead the charge in crypto and stablecoin adoption within aviation. Allowing customers to pay for flights with stablecoins isn’t just about embracing the future of travel – it’s about making the experience faster, cheaper, and more inclusive for travelers worldwide.”

    International visitors represent the majority of Bermuda’s 200,000+ annual air arrivals, many of whom currently face 1–3% foreign transaction fees on credit card bookings.12 By offering a direct stablecoin payment option, BermudAir will offer the opportunity to eliminate those costs and deliver a smoother booking experience for its globally diverse clientele. Stablecoin payments also process 24/7, ensuring ticket purchases can be confirmed in minutes without banking delays, a clear win for travelers and tourism operators.

    Zero Hash, the leading crypto, stablecoin and tokenization infrastructure provider, will power the conversion and settlement of these transactions. Zero Hash Worldwide Ltd., which holds a Class F license issued by the Bermuda Monetary Authority (BMA) under the Digital Asset Business Act, will enable BermudAir to accept digital dollar payments in a compliant, secure manner.

    Zero Hash views stablecoins as a core Alternative Payment Method (APM) poised for mass adoption in everyday transactions. The numbers support this shift: over the past 24 months, nearly 750 million people have gained access to stablecoins and crypto via a primary account on platforms like Revolut, NuBank, Robinhood, PayPal, Stripe, and Venmo. In just the last 30 days, 29.2 million unique wallets processed 705 million stablecoin transactions – totaling $3.3 trillion in volume.3

    The travel industry is uniquely positioned to lead this adoption – an early mover in loyalty programs, digital wallets, and cross-border innovation, it has a proven track record of embracing financial infrastructure before the mainstream.

    “Zero Hash is thrilled to power this first-of-its-kind stablecoin payment offering in the airline industry,” said Edward Woodford, Founder and CEO of Zero Hash. “This partnership with BermudAir exemplifies the convergence of digital finance innovation. By leveraging our stablecoin payments infrastructure, BermudAir can deliver the seamless payments and global accessibility that customers expect in the future of travel. It’s a shining example of stablecoins making a real-world impact, and we’re excited to help empower Bermudian businesses through compliant, cutting-edge technology.”

    The announcement comes amid a broader movement to onboard Bermudian businesses into digital finance. Bermuda’s government has cultivated a robust regulatory framework for fintech, making the island a hub for crypto adoption and innovation.

    The Bermuda Digital Finance Forum, hosted by Penrose Partners, SALT and The Decentralized AI Society (DAIS), is bringing community leaders together to empower local businesses and residents to leverage digital finance.

    This effort builds on BermudAir’s track record of innovation in digital finance, including a prior issuance of stablecoin bond tokens in partnership with crypto custodian XBTO.

    BermudAir’s stablecoin payment feature will be accessed by booking on flybermudair.com and the airline’s mobile app. Travelers will simply choose the stablecoin payment option during checkout, and Zero Hash will seamlessly handle the crypto-to-fiat settlement in real time. Both companies anticipate that this convenience will appeal to overseas travelers and business flyers, who can avoid exchanging currencies or incurring bank fees by paying directly in digital dollars.


    About Zero Hash
    Zero Hash is the leading infrastructure provider for crypto, stablecoin, and tokenized assets. Its API and embeddable dev-kit enables innovators to easily launch solutions across cross-border payments, commerce, trading, remittance, payroll, tokenization and on/off-ramps.

    Zero Hash powers solutions for some of the largest and innovative companies including Interactive Brokers, Stripe, Shift4, Franklin Templeton, Felix Pago, Kalshi and LightSpark. Zero Hash Holdings is backed by investors, including Point72 Ventures, Bain Capital Ventures, and NYCA.

    Zero Hash Worldwide Ltd. holds a Class F license issued by the Bermuda Monetary Authority (BMA) under the Digital Asset Business Act 2018 of Bermuda.

    Zero Hash Trust Company LLC has been approved by the North Carolina Commissioner of Banks as a non-depository trust company.

    Zero Hash LLC is a FinCen-registered Money Service Business and a regulated Money Transmitter that can operate in 51 U.S. jurisdictions. Zero Hash LLC and Zero Hash Liquidity Services LLC are licensed to engage in virtual currency business activity by the New York State Department of Financial Services. In Canada, Zero Hash LLC is registered as a Money Service Business with FINTRAC.

    Zero Hash Australia Pty Ltd. is registered with AUSTRAC as a Digital Currency Exchange Provider, with DCE registered provider number DCE100804170-001. Zero Hash Australia Pty Ltd. is registered on the New Zealand register of financial service providers, with Financial Service Provider (FSP) number FSP1004503. Zero Hash Europe B.V. is registered as a Virtual Asset Services Provider (VASP) by the Dutch Central Bank (Relation number: R193684). Zero Hash Europe Sp. Zoo is registered as a VASP by the Tax Administration Chamber of Poland in Katowice (Registration number RDWW – 1212).

    Learn more by visiting zerohash.com or following us on X @ZeroHashX

    About BermudAir
    BermudAir is Bermuda’s airline, committed to redefining the travel experience. With a fleet of Embraer E175 and E190 aircraft renowned for exceptional performance and passenger comfort, BermudAir exemplifies its commitment to excellence. Operating convenient flights to and from Westchester Country Airport, Boston Logan International Airport, Fort Lauderdale-Hollywood International Airport, Orlando International Airport, Charleston International Airport, Raleigh-Durham International Airport, Bradley International Airport and Baltimore/Washington International Thurgood Marshall Airport, Rhode Island T. F. Green International Airport, and Richmond International Airport. BermudAir enhances connectivity to the U.S. East Coast, contributing to the growth and prosperity of Bermuda. BermudAir also operates flights to Toronto Pearson International Airport, Halifax Stanfield International Airport, and Montréal-Pierre Elliott Trudeau International Airport in Canada. With a dedication to exceptional service and curated onboard offerings that showcase the island’s renowned hospitality and varied food and beverages available locally, BermudAir provides an unparalleled travel experience. For more information, and to book flights, please visit www.flybermudair.com.


    1gotobermuda 2024 Visitor Arrivals Report
    2bankrate.com
    3Artemis Terminal

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Blue Mantis Expands Leadership Team to Drive Growth, Innovation and Market Impact

    Source: GlobeNewswire (MIL-OSI)

    PORTSMOUTH, N.H., May 08, 2025 (GLOBE NEWSWIRE) — Blue Mantis, a leading provider of digital strategy and services specializing in managed services, cybersecurity and cloud solutions, today announced the appointments of Ruya Barrett as Chief Marketing Officer (CMO) and Scott Pintsopoulos as Vice President (VP) of Sales. Barrett and Pintsopoulos both report to Chief Revenue Officer (CRO) Terry Richardson. The appointments reinforce Blue Mantis’ commitment to scaling its go-to-market team and enhancing its ability to deliver innovative, customer-focused solutions to mid-market enterprises.

    “Blue Mantis is committed to leading and advising our clients as they take on the often-challenging task of IT modernization,” said Terry Richardson, Blue Mantis CRO. “Scott has a proven track record of driving enterprise growth and delivering strategic, customer-focused solutions. His leadership, combined with Ruya’s marketing expertise, will help Blue Mantis continue to scale to serve more enterprises undergoing digital transformation initiatives. Their collective customer-centric mindset will further enhance our ability to deliver innovative solutions and drive measurable business outcomes.”

    Elevating Blue Mantis’ Brand and Market Impact

    As Chief Marketing Officer, Ruya Barrett is responsible for driving Blue Mantis’ strategic marketing vision, shaping the company’s brand identity and strengthening its market positioning. She leads all internal and external marketing functions, including content, demand generation, public relations, social media, and marketing analytics with a focus on building upon Blue Mantis’ strong reputation for long-term client partnerships.

    Barrett brings over 20 years of experience accelerating growth for both startups and Fortune 500 companies. Her career spans leadership roles at EMC, VCE and HPE, where she applied her deep technical expertise and full-lifecycle product knowledge to develop innovative go-to-market strategies. Most recently, she served as Vice President of International Field Marketing and Demand Generation at Dell, where she led a global program that contributed over $1 billion to the company’s marketing pipeline.

    Spearheading Revenue Growth and Sales Strategy

    As VP of Sales, Pintsopoulos is contributing to Blue Mantis’ growth and market expansion by driving revenue growth, optimizing sales strategies and continuing to expand the company’s overall market presence. Pintsopoulos brings a strong track record of building positive cultures and high-performance teams and is an accomplished sales, operations and customer success leader. Throughout his career, Pintsopoulos has worked within early-stage equity-backed organizations, as well as mature regional, national and global companies.

    Scott brings over 23 years of Executive Management experience to Blue Mantis across his 32 year career in IT Services. Most recently, Pintsopoulos was chief revenue officer (CRO) of Bluum, an education technology solutions provider, where he led all go-to-market (GTM) functions including field sales, marketing, sales enablement and transformation and drove over $600 million in annual revenue. Prior to Bluum, Pintsopoulos held Executive Leadership positions at Udacity, NWN and NetTeks/ INX.

    About Blue Mantis
    Blue Mantis is a security-first, IT solutions and services provider with a 30+ year history of successfully helping clients achieve business modernization by applying next-generation technologies including managed services, cybersecurity, cloud and collaboration. Headquartered in Portsmouth, New Hampshire, the company provides digital technology services and strategic guidance to ensure clients quickly adapt and grow through automation and innovation. Blue Mantis partners with more than 1,500 leading mid-market and enterprise organizations in a multitude of vertical industries and is backed by leading private equity firm, Recognize. For more information about Blue Mantis and its services, please visit www.bluemantis.com.

    Contact
    Shannon Cieciuch
    Touchdown PR for Blue Mantis
    Bluemantis@touchdownpr.com

    The MIL Network –

    May 9, 2025
  • MIL-OSI: KH Group: Indoor Group updated its financing agreement

    Source: GlobeNewswire (MIL-OSI)

    KH Group Plc
    Press Release 8 May 2025 at 3:00 pm EEST

    KH Group: Indoor Group updated its financing agreement

    KH Group’s subsidiary Indoor Group has updated its agreement with the financing provider. In accordance with the updated agreement the financing provider will not demand the repayment of loans, provided that certain conditions are met. The validity of the agreement has been extended until 31 August 2025.

    The parties have engaged in negotiations on the terms of validity of Indoor Group’s financing for the duration of the sale process. Due to a breach of covenants on 30 September 2024, there is uncertainty in Indoor Group’s financing. The financing provider has the right to demand repayment of the loans at the expiration of the agreement, which may have an impact on Indoor Group’s ability to continue as a going concern. Indoor Group’s financing situation does not have immediate impacts on KH Group’s continuing operations, as the Group companies have ring-fenced financing.

    KH GROUP PLC

    Further information:
    CEO Ville Nikulainen, tel. +358 40 045 9343

    Distribution:
    Major media
    www.khgroup.com

    KH Group Plc is a Nordic conglomerate operating in the business areas of KH-Koneet, Nordic Rescue Group and Indoor Group. We are a leading supplier of construction and earth-moving equipment, rescue vehicle manufacturer as well as furniture and interior decoration retailer. The objective of our strategy is to create an industrial group around the business of KH-Koneet. KH Group’s share is listed on Nasdaq Helsinki.

    The MIL Network –

    May 9, 2025
  • MIL-OSI: xSuite Group Partners with Trenex Consulting to Expand Global Reach

    Source: GlobeNewswire (MIL-OSI)

    Press Release xSuite

    xSuite Group Partners with Trenex Consulting to Expand Global Reach

    The Finance Automation consulting firm from the USA will now offer SAP user companies the software solutions of the German specialist for automated P2P processes

    Ahrensburg, Germany / Metairie, LA/USA – May 8, 2025 – xSuite Group and Trenex Consulting LLC entered into a partnership agreement in March 2025. As a new xSuite Solution Partner, Trenex will distribute, implement, and support xSuite’s solutions for automated invoice and procurement processes as well as archiving across the USA, Europe and the APAC region. Through this partnership with xSuite Group, Trenex is strategically repositioning itself within the SAP ecosystem and expanding its service portfolio for international customers.

    Headquartered in Louisiana, USA, Trenex Consulting is a globally operating IT advisory firm with deep expertise in financial process automation and SAP-driven business optimization. As companies worldwide face the challenges of digital transformation and transition to SAP S/4HANA, many are searching for modern, future-ready alternatives to legacy systems.

    Expanding SAP-Centric Capabilities

    The partnership allows Trenex to offer certified SAP solutions from xSuite that are compatible with all SAP deployment models—whether on-premises, in the cloud, or hybrid. xSuite’s modular and scalable P2P and archiving solutions stand out for their flexibility, global applicability, and futuristic product roadmap, making them ideal for companies to modernize their core financial processes ahead of their S/4 HANA migration.

    Shared Vision for Innovation and Client Value

    “We are excited to welcome Trenex as a solution partner that combines deep market knowledge with a strong track record in business process automation,” said Andreas Nowottka, Managing Director at xSuite Group. “Their commitment to delivering innovative and future-proof solutions to SAP clients around the globe aligns perfectly with xSuite’s mission.

    “Our clients demand state-of-the-art solutions—both technologically and functionally—regardless of whether they run SAP on-premises, in the cloud, or in a hybrid setup,” added Frank (Cheng) Fan, General Manager of Trenex Consulting LLC. “xSuite checks all the boxes: modular architecture, SAP certification, and international compatibility. We also greatly value their collaborative approach and future-driven roadmap, which will empower us to support our clients over the long term.”

    About Trenex Consulting LLC
    Trenex Consulting is a global IT solutions provider specializing in ERP, EPM, Financial Process Automation (FPA), and Robotic Process Automation (RPA). With deep SAP expertise, a multilingual team, and around-the-clock support, Trenex delivers tailored services to help businesses drive digital transformation and optimize core operations worldwide. https://www.trenexconsulting.com/

    About xSuite Group
    With offices in Asia, Europe, and the U.S., xSuite is a leading innovator in optimizing SAP-based P2P workflows. The company provides software solutions and implementation services to over 1,600 clients worldwide, making it a trusted partner in modernizing AP systems and automating manual, paper-based processes.

    Press Contact:
    xSuite Group / Headquarters

    Barbara Wirtz
    Marketing & PR
    Tel. +49 (0)4102/88 38 36
    barbara.wirtz@xsuite.com
    www.xsuite.com

    Partner Contact:
    xSuite Group / International

    Tony Cheung
    Global Vice President
    Enterprise Accounts & Strategic Alliances
    Tel. +44 7561 893170
    tony.cheung@xsuite.com
    www.xsuite.com

    Attachment

    • Frank (Cheng) Fan, General Manager Trenex Consulting LLC (l) and Thomas Radestock, CSO xSuite Group.

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Parex Resources Announces First Quarter Results, Declaration of Q2 2025 Dividend, and Operational Update

    Source: GlobeNewswire (MIL-OSI)

    CALGARY, Alberta, May 08, 2025 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce its financial and operating results for the three-month period ended March 31, 2025, the declaration of its Q2 2025 regular dividend of C$0.385 per share, as well as an operational update. All amounts herein are in United States Dollars (“USD”) unless otherwise stated.

    “We entered the year with a disciplined and diversified plan aimed at delivering steady performance, and given current market volatility, are focused on sustaining base production and maintaining flexibility,” commented Imad Mohsen, President & Chief Executive Officer.

    “After a measured first quarter, drilling activity is increasing consistent with our budget. The recent tuck-in acquisition of LLA-32, an asset integral to our development plans, along with encouraging exploration results, represent key milestones that will drive near-term production. While we are well-positioned to deliver a strong second half, we will closely monitor commodity prices and our capital allocation throughout the year to maximize shareholder value.”

    Key Highlights

    • Generated Q1 2025 funds flow provided by operations (“FFO”)(1) of $122 million and FFO per share(2)(3) of $1.24.
    • Tracking to deliver FY 2025 average production guidance of 43,000 to 47,000 boe/d; YTD 2025 average production is approximately 43,100 boe/d(5)(7), with plans intact for a growing H2 2025 production profile.
    • Positive initial results at two prospects in the Southern Llanos, which are driving near-field exploration momentum.
    • Capital expenditure(6) guidance for FY 2025 remains at $285 to $315 million, though the Company continues to monitor commodity prices and could revise lower if warranted by market conditions.
    • Executed a tuck-in acquisition of the remaining working interest at LLA-32 for total consideration of $16 million.

    Q1 2025 Results

    • Average oil & natural gas production was 43,658 boe/d(7).
    • Realized net income of $81 million or $0.82 per share basic(3).
    • Generated FFO(1) of $122 million and FFO per share(2)(3) of $1.24.
    • Current taxes were $12 million; at current Brent crude oil strip pricing, the Company expects its FY 2025 effective current tax rate to be 0-3%.
    • Produced an operating netback(2) of $39.40/boe and an FFO netback(2) of $30.90/boe from an average Brent price of $74.98/bbl.
    • Incurred $57 million of capital expenditures(6), primarily from activities at Cabrestero, Capachos, and LLA-34.
    • Generated $65 million of free funds flow(6) that was used for return of capital initiatives, $10 million of bank debt repayment and increasing working capital surplus(1); working capital surplus(1) was $69 million and cash $81 million at quarter end.
    • Paid a C$0.385 per share(4) regular quarterly dividend and repurchased 524,900 shares.

    (1) Capital management measure. See “Non-GAAP and Other Financial Measures Advisory.”
    (2) Non-GAAP ratio. See “Non-GAAP and Other Financial Measures Advisory.”
    (3) Based on weighted average basic shares for the period.
    (4) Supplementary financial measure. See “Non-GAAP and Other Financial Measures Advisory.”
    (5) Based on Q1 2025 actuals and estimated April 2025 average production; rounded for presentation purposes.
    (6) Non-GAAP financial measure. See “Non-GAAP and Other Financial Measures Advisory.”
    (7) See “Operational and Financial Highlights” for a breakdown of production by product type.

    Operational and Financial Highlights Three Months Ended
    (unaudited) Mar. 31, Mar. 31, Dec. 31,
      2025 2024 2024
    Operational      
    Average daily production      
    Light Crude Oil and Medium Crude Oil (bbl/d) 10,650   7,237   9,550  
    Heavy Crude Oil (bbl/d) 32,207   45,543   34,882  
    Crude Oil (bbl/d) 42,857   52,780   44,432  
    Conventional Natural Gas (mcf/d) 4,806   3,348   5,190  
    Oil & Gas (boe/d)(1) 43,658   53,338   45,297  
           
    Operating netback ($/boe)      
    Reference price – Brent ($/bbl) 74.98   81.87   74.01  
    Oil & gas sales(4) 67.29   70.80   63.73  
    Royalties(4) (9.22 ) (11.21 ) (9.43 )
    Net revenue(4) 58.07   59.59   54.30  
    Production expense(4) (14.41 ) (12.64 ) (15.53 )
    Transportation expense(4) (4.26 ) (3.40 ) (3.87 )
    Operating netback ($/boe)(2) 39.40   43.55   34.90  
           
    Funds flow provided by operations netback ($/boe)(2) 30.90   31.32   32.39  
           
    Financial ($000s except per share amounts)      
           
    Net income 80,629   60,093   (69,051 )
    Per share – basic(6) 0.82   0.58   (0.70 )
           
    Funds flow provided by operations(5) 121,944   148,307   141,201  
    Per share – basic(2)(6) 1.24   1.43   1.43  
           
    Capital expenditures(3) 57,054   85,421   82,110  
           
    Free funds flow(3) 64,890   62,886   59,091  
           
    EBITDA(3) 139,032   192,078   (10,419 )
    Adjusted EBITDA(3) 135,407   188,228   137,312  
           
    Long-term inventory expenditures (4,648 ) 3,843   (2,569 )
           
    Dividends paid 26,365   28,531   26,658  
    Per share – Cdn$(4)(6) 0.385   0.375   0.385  
           
    Shares repurchased 5,239   15,291   16,408  
    Number of shares repurchased (000s) 525   920   1,692  
           
    Outstanding shares (end of period) (000s)      
    Basic 97,814   102,914   98,339  
    Weighted average basic 98,115   103,474   99,063  
    Diluted(8) 99,105   103,829   99,238  
           
    Working capital surplus (deficit)(5) 69,040   55,901   59,397  
    Bank debt(7) 50,000   60,000   60,000  
    Cash 81,025   61,052   98,022  

    (1) Reference to crude oil or natural gas in the above table and elsewhere in this press release refer to the light and medium crude oil and heavy crude oil and conventional natural gas, respectively, product types as defined in National Instrument 51-101 – Standards of Disclosure for Oil and Gas Activities.
    (2) Non-GAAP ratio. See “Non-GAAP and Other Financial Measures Advisory”.
    (3) Non-GAAP financial measure. See “Non-GAAP and Other Financial Measures Advisory”.
    (4) Supplementary financial measure. See “Non-GAAP and Other Financial Measures Advisory”.
    (5) Capital management measure. See “Non-GAAP and Other Financial Measures Advisory”.
    (6) Per share amounts (with the exception of dividends) are based on weighted average common shares.
    (7) Borrowing limit of $240.0 million as of March 31, 2025.
    (8) Diluted shares as stated include common shares and stock options outstanding at period-end. The March 31, 2025 closing stock price was C$13.42 per share.

    LLA-32 Tuck-In Acquisition

    On March 14, 2025, Parex executed a tuck-in acquisition for the remaining working interest at LLA-32 for total consideration of $16 million. LLA-32 is located to the north and adjacent to the Company’s core LLA-34 and Cabrestero blocks.

    The strategic rationale for the acquisition was to gain full control of the asset, grow production, expand inventory, and add low-cost recompletion opportunities.

    Following the close of the acquisition, Parex started a workover program with positive results thus far, and in Q2 2025, initiated a five-well development campaign. Current production from LLA-32 is roughly 4,000 boe/d(1).

    Operational Update

    2025 Corporate Guidance & Outlook

    While Parex’s 2025 corporate guidance of average production of 43,000 to 47,000 boe/d and capital expenditures of $285 to $315 million remains unchanged as previously disclosed, the Company is closely monitoring oil price volatility to ensure that project economics remain robust.

    Given the conventional nature of Parex’s business and the structure of its drilling and service contracts, optionality exists to adjust activity levels in response to prevailing market conditions in order to ensure efficient capital allocation and maximization of shareholder value.

    For Q2 2025, average production is expected to be similar to Q1 2025, supported by increased development activity and preliminary near-field exploration success.

    Operational Update

    Average production for Q1 2025 of 43,658 boe/d(2) was in line with Management expectations. The quarter progressed steadily, which is aligned with the Company’s activity plan to support a growing H2 2025 production profile, as previously disclosed.

    April 2025 average production was 41,400 boe/d(3), with production generally consistent with lower activity levels and modest capital outlay in Q1 2025, as well as higher than budgeted downtime due to weather factors. Downtime levels have normalized and initial average production rates in May are roughly 43,200 boe/d(4).

    With budgeted activity underway, operational momentum is expected to build through the remainder of the year. Parex currently has three drilling rigs operating (two operated and one non-operated). In addition to enhanced oil recovery initiatives at Cabrestero and LLA-34, activity for Q2 2025 is primarily focused on development wells that are planned to be sequential in nature and located on existing pads that enable efficient production across parallel operations.

    Near-Term Development Activity

    • Drilling at LLA-34 that is expected to continue through Q2 2025, resulting in the expected completion of six in-fill wells;
    • Commencing operations at LLA-32, with the first well of the campaign to be completed in late Q2 2025; and
    • Achieving initial access in the Putumayo, with activity starting with a workover rig in Q2 2025.

    Near-Field Exploration Program plus Follow-Up Drilling

    As part of this program, two separate prospects have yielded positive initial results in the Southern Llanos, where operations are ongoing:

    • On LLA-74, a prospect was drilled successfully.
      • Initial production began in early May, with current output of approximately 1,200 bbl/d of heavy crude oil(5).
    • Also on LLA-74, a prospect was drilled via a vertical well.
      • Based on management’s positive initial assessment, the program has progressed with the design of two horizontal wells to optimize production and recovery.
      • The first follow-up horizontal well is currently being drilled, with expected production in late May.

    (1) Estimated average production for April 1, 2025 to April 30, 2025; light & medium crude oil: ~3,409 bbl/d, conventional natural gas: ~3,544 mcf/d; rounded for presentation purposes.
    (2) See “Operational and Financial Highlights” for a breakdown of production by product type.
    (3) Estimated average production for April 1, 2025 to April 30, 2025; light & medium crude oil: ~10,099 bbl/d, heavy crude oil: ~30,541 bbl/d, conventional natural gas: ~4,557 mcf/d; rounded for presentation purposes.
    (4) Estimated average production for May 1, 2025 to May 6, 2025; light & medium crude oil: ~10,538 bbl/d, heavy crude oil: ~31,869 bbl/d, conventional natural gas: ~4,756 mcf/d; rounded for presentation purposes.
    (5) Short-term production rate. See “Oil & Gas Matters Advisory.”

    Risk Management

    For Q1 2025, Parex entered into a Brent crude oil hedge to manage price risk on approximately 25% of planned net crude oil production, utilizing a Brent put spread at $60/bbl and $70/bbl. For Q2 2025, Parex entered into similar hedges for the months of April 2025 and May 2025.

    Parex plans to regularly evaluate market conditions, operational requirements, and other pertinent factors, to assess the need for any additional hedging actions as it progresses through 2025.

    Return of Capital Update

    Q2 2025 Dividend

    Parex’s Board of Directors have approved a Q2 2025 regular dividend of C$0.385 per share to shareholders of record on June 9, 2025, to be paid on June 16, 2025. This regular dividend payment to shareholders is designated as an “eligible dividend” for purposes of the Income Tax Act (Canada).

    Normal Course Issuer Bids

    In 2025, Parex has repurchased approximately 0.7 million shares under its NCIBs, for total consideration of roughly C$10 million.

    Q1 2025 Results – Conference Call & Webcast

    Parex will host a conference call and webcast to discuss its Q1 2025 results on Thursday, May 8, 2025, beginning at 9:30 am MT (11:30 am ET). To participate in the conference call or webcast, please see the access information below:

    Conference ID: 5403995
    Participant Toll-Free Dial-In Number: 1-646-307-1963
    Participant Dial-In Number: 1-647-932-3411
    Webcast: https://events.q4inc.com/attendee/867962059

    Annual General Meeting

    On Thursday, May 8, 2025, Parex will hold its Annual General Meeting at 11:00 am MT (1:00 pm ET) both in-person and virtually. Participants may attend at the 4th Floor Conference Center, Eight Avenue Place, East Tower, 525, 8th Ave SW, Calgary, Alberta – and virtual participants can join through the following link: https:meetnow.global/M4SULLK.

    Additional information regarding the Annual General Meeting, including meeting materials, can be found at www.parexresources.com under Investors.

    About Parex Resources Inc.

    Parex is one of the largest independent oil and gas companies in Colombia, focusing on sustainable conventional production. The Company’s corporate headquarters are in Calgary, Canada, with an operating office in Bogotá, Colombia. Parex shares trade on the Toronto Stock Exchange under the symbol PXT.

    For more information, please contact:

    Mike Kruchten
    Senior Vice President, Capital Markets & Corporate Planning
    Parex Resources Inc.
    403-517-1733
    investor.relations@parexresources.com

    Steven Eirich
    Senior Investor Relations & Communications Advisor
    Parex Resources Inc.
    587-293-3286
    investor.relations@parexresources.com

    NOT FOR DISTRIBUTION OR FOR DISSEMINATION IN THE UNITED STATES

    Non-GAAP and Other Financial Measures Advisory

    This press release uses various “non-GAAP financial measures”, “non-GAAP ratios”, “supplementary financial measures” and “capital management measures” (as such terms are defined in NI 52-112), which are described in further detail below. Such measures are not standardized financial measures under IFRS and might not be comparable to similar financial measures disclosed by other issuers. Investors are cautioned that non-GAAP financial measures should not be construed as alternatives to or more meaningful than the most directly comparable GAAP measures as indicators of Parex’s performance.

    These measures facilitate management’s comparisons to the Company’s historical operating results in assessing its results and strategic and operational decision-making and may be used by financial analysts and others in the oil and natural gas industry to evaluate the Company’s performance. Further, management believes that such financial measures are useful supplemental information to analyze operating performance and provide an indication of the results generated by the Company’s principal business activities.

    Set forth below is a description of the non-GAAP financial measures, non-GAAP ratios, supplementary financial measures and capital management measures used in this press release.

    Non-GAAP Financial Measures

    Capital expenditures, is a non-GAAP financial measure which the Company uses to describe its capital costs associated with oil and gas expenditures. The measure considers both property, plant and equipment expenditures and exploration and evaluation asset expenditures which are items in the Company’s statement of cash flows for the period and is calculated as follows:

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Property, plant and equipment expenditures $ 44,951   $ 40,831   $ 62,799
    Exploration and evaluation expenditures   12,103     44,590     19,311
    Capital expenditures $ 57,054   $ 85,421   $ 82,110


    Free funds flow,
    is a non-GAAP financial measure that is determined by funds flow provided by operations less capital expenditures. The Company considers free funds flow to be a key measure as it demonstrates Parex’s ability to fund return of capital, such as the normal course issuer bid and dividends, without accessing outside funds and is calculated as follows:

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Cash provided by operating activities $ 87,621   $ 97,412   $ 67,847
    Net change in non-cash assets and liabilities   34,323     50,895     73,354
    Funds flow provided by operations   121,944     148,307     141,201
    Capital expenditures   57,054     85,421     82,110
    Free funds flow $ 64,890   $ 62,886   $ 59,091


    EBITDA
    , is a non-GAAP financial measure that is defined as net income (loss) adjusted for finance income and expenses, other expenses, income tax expense (recovery) and depletion, depreciation and amortization.

    Adjusted EBITDA, is a non-GAAP financial measure defined as EBITDA adjusted for non-cash impairment charges, share-based compensation expense (recovery), unrealized foreign exchange gains (losses) and unrealized gains (losses) on risk management contracts.

    The Company considers EBITDA and Adjusted EBITDA to be key measures as they demonstrate Parex’s profitability before finance income and expenses, taxes, depletion, depreciation and amortization and other non-cash items. A reconciliation from net income to EBITDA and Adjusted EBITDA is as follows:

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Net income (loss) $ 80,629     $ 60,093     $ (69,051 )
    Adjustments to reconcile net income (loss) to EBITDA:          
    Finance income   (1,297 )     (1,257 )     (998 )
    Finance expense   5,056       4,455       4,318  
    Other expenses   1,147       739       2,208  
    Income tax expense (recovery)   3,078       75,817       (880 )
    Depletion, depreciation and amortization   50,419       52,231       53,984  
    EBITDA $ 139,032     $ 192,078     $ (10,419 )
    Non-cash impairment charges   —       —       137,841  
    Share-based compensation expense (recovery)   2,092       (2,463 )     6,149  
    Unrealized foreign exchange (gain) loss   (4,919 )     (1,387 )     2,581  
    Unrealized (gain) loss on risk management contracts   (798 )     —       1,160  
    Adjusted EBITDA $ 135,407     $ 188,228     $ 137,312  


    Non-GAAP Ratios

    Operating netback per boe, is a non-GAAP ratio that the Company considers to be a key measure as it demonstrates Parex’ profitability relative to current commodity prices. Parex calculates operating netback per boe as operating netback (calculated as oil and natural gas sales from production, less royalties, operating, and transportation expense) divided by the total equivalent sales volume including purchased oil volumes for oil and natural gas sales price and transportation expense per boe and by the total equivalent sales volume excluding purchased oil volumes for royalties and operating expense per boe.

    Funds flow provided by operations netback per boe or FFO netback per boe, is a non-GAAP ratio that includes all cash generated from operating activities and is calculated before changes in non-cash assets and liabilities, divided by produced oil and natural gas sales volumes. The Company considers funds flow provided by operations netback per boe to be a key measure as it demonstrates Parex’s profitability after all cash costs relative to current commodity prices.

    Basic funds flow provided by operations per share or FFO per share, is a non-GAAP ratio that is calculated by dividing funds flow provided by operations by the weighted average number of basic shares outstanding. Parex presents basic funds flow provided by operations per share whereby per share amounts are calculated using weighted-average shares outstanding, consistent with the calculation of earnings per share. The Company considers basic funds flow provided by operations per share or FFO per share to be a key measure as it demonstrates Parex’s profitability after all cash costs relative to the weighted average number of basic shares outstanding.

    Capital Management Measures

    Funds flow provided by operations, is a capital management measure that includes all cash generated from operating activities and is calculated before changes in non-cash assets and liabilities. The Company considers funds flow provided by operations to be a key measure as it demonstrates Parex’s profitability after all cash costs. A reconciliation from cash provided by operating activities to funds flow provided by operations is as follows:

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Cash provided by operating activities $ 87,621   $ 97,412   $ 67,847
    Net change in non-cash assets and liabilities   34,323     50,895     73,354
    Funds flow provided by operations $ 121,944   $ 148,307   $ 141,201

    Working capital surplus, is a capital management measure which the Company uses to describe its liquidity position and ability to meet its short-term liabilities. Working capital surplus is defined as current assets less current liabilities.

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Current assets $ 259,256   $ 276,113   $ 245,943
    Current liabilities   190,216     220,212     186,546
    Working capital surplus $ 69,040   $ 55,901   $ 59,397


    Supplementary Financial Measures

    “Oil and natural gas sales price per boe” is comprised of total commodity sales from oil and natural gas production, as determined in accordance with IFRS, divided by the total oil and natural gas sales volumes including purchased oil volumes.

    “Royalties per boe” is comprised of royalties, as determined in accordance with IFRS, divided by the total equivalent sales volume and excludes purchased oil volumes.

    “Net revenue per boe” is comprised of net revenue, as determined in accordance with IFRS, divided by the total equivalent sales volume and includes purchased oil volumes.

    “Production expense per boe” is comprised of production expense, as determined in accordance with IFRS, divided by the total equivalent sales volume and excludes purchased oil volumes.

    “Transportation expense per boe” is comprised of transportation expense, as determined in accordance with IFRS, divided by the total equivalent sales volumes including purchased oil volumes.

    “Dividends paid per share” is comprised of dividends declared, as determined in accordance with IFRS, divided by the number of shares outstanding at the dividend record date.

    Oil & Gas Matters Advisory

    The term “Boe” means a barrel of oil equivalent on the basis of 6 Mcf of natural gas to 1 barrel of oil (“bbl”). Boe’s may be misleading, particularly if used in isolation. A boe conversation ratio of 6 Mcf: 1 Bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. Given the value ratio based on the current price of crude oil as compared to natural gas is significantly different from the energy equivalency of 6 Mcf: 1Bbl, utilizing a conversion ratio at 6 Mcf: 1 Bbl may be misleading as an indication of value.

    This press release contains a number of oil and gas metrics, including, operating netbacks and FFO netbacks. These oil and gas metrics have been prepared by management and do not have standardized meanings or standard methods of calculation and therefore such measures may not be comparable to similar measures used by other companies and should not be used to make comparisons. Such metrics have been included herein to provide readers with additional measures to evaluate the Company’s performance; however, such measures are not reliable indicators of the future performance of the Company and future performance may not compare to the performance in previous periods and therefore such metrics should not be unduly relied upon. Management uses these oil and gas metrics for its own performance measurements and to provide security holders with measures to compare the Company’s operations over time. Readers are cautioned that the information provided by these metrics, or that can be derived from the metrics presented in this news release, should not be relied upon for investment or other purposes.

    Any reference in this press release to short-term production rates are useful in confirming the presence of hydrocarbons, however such rates are not determination of the rates at which such wells will continue production and decline thereafter and readers are cautioned not to place reliance on such rates in calculating the aggregate production of Parex.

    Distribution Advisory

    The Company’s future shareholder distributions, including but not limited to the payment of dividends and the acquisition by the Company of its shares pursuant to an NCIB, if any, and the level thereof is uncertain. Any decision to pay further dividends on the common shares (including the actual amount, the declaration date, the record date and the payment date in connection therewith and any special dividends) or acquire shares of the Company will be subject to the discretion of the Board of Directors of Parex and may depend on a variety of factors, including, without limitation the Company’s business performance, financial condition, financial requirements, growth plans, expected capital requirements and other conditions existing at such future time including, without limitation, contractual restrictions and satisfaction of the solvency tests imposed on the Company under applicable corporate law. Further, the actual amount, the declaration date, the record date and the payment date of any dividend are subject to the discretion of the Board. There can be no assurance that the Company will pay dividends or repurchase any shares of the Company in the future.

    Advisory on Forward Looking Statements

    Certain information regarding Parex set forth in this document contains forward-looking statements that involve substantial known and unknown risks and uncertainties. The use of any of the words “plan”, “expect”, “prospective”, “project”, “intend”, “believe”, “should”, “anticipate”, “estimate”, “forecast”, “guidance”, “budget” or other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking statements. Such statements represent Parex’s internal projections, estimates or beliefs concerning, among other things, future growth, results of operations, production, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, plans for and results of drilling activity, environmental matters, business prospects and opportunities. These statements are only predictions and actual events or results may differ materially. Although the Company’s management believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievement since such expectations are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause Parex’s actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, Parex.

    In particular, forward-looking statements contained in this document include, but are not limited to, statements with respect to: the Company’s focus, plans, priorities and strategies; average production guidance and capital expenditure guidance; expectations and plans regarding the Company’s drilling activity, the Company’s production profile, prospects in the Southern Llanos, the LLA-32 tuck-in acquisition, drilling and programs at LLA-34, LLA-32, Putumayo, and LLA-74; expectations about the Company’s FY 2025 tax rate; plans with respect to assessing the need for additional hedging in 2025; the anticipated terms of the Company’s Q2 2025 regular quarterly dividend, including its expectation that it will be designated as an “eligible dividend”; and the anticipated date and time of Parex’s conference call to discuss Q1 2025 results.

    These forward-looking statements are subject to numerous risks and uncertainties, including but not limited to, the impact of general economic conditions in Canada and Colombia; an unpredictable tariff and trade environment; prolonged volatility in commodity prices; industry conditions including changes in laws and regulations including adoption of new environmental laws and regulations, and changes in how they are interpreted and enforced in Canada and Colombia; determinations by OPEC and other countries as to production levels; competition; lack of availability of qualified personnel; the results of exploration and development drilling and related activities; obtaining required approvals of regulatory authorities in Canada and Colombia; the risks associated with negotiating with foreign governments as well as country risk associated with conducting international activities; volatility in market prices for oil; fluctuations in foreign exchange or interest rates; environmental risks; changes in income tax laws or changes in tax laws and incentive programs relating to the oil industry; changes to pipeline capacity; ability to access sufficient capital from internal and external sources; failure of counterparties to perform under contracts; the risk that Brent oil prices may be lower than anticipated; the risk that Parex’s evaluation of its existing portfolio of development and exploration opportunities may not be consistent with its expectations; the risk that Parex may not have sufficient financial resources in the future to provide distributions to its shareholders; the risk that the Board may not declare dividends in the future or that Parex’s dividend policy changes; the risk that Parex may not be responsive to changes in commodity prices; the risk that Parex may not meet its production guidance for the year ended December 31, 2025; the risk that Parex’s 2025 capital expenditures may be greater or less than anticipated; the risk that plans and expectations related to Parex’s drilling program as disclosed herein do not materialize as expected and/or at all; and other factors, many of which are beyond the control of the Company.

    Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect Parex’s operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR+ website (www.sedarplus.ca).

    Although the forward-looking statements contained in this document are based upon assumptions which Management believes to be reasonable, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. With respect to forward-looking statements contained in this document, Parex has made assumptions regarding, among other things: current and anticipated commodity prices and royalty regimes; availability of skilled labour; timing and amount of capital expenditures; future exchange rates; the price of oil, including the anticipated Brent oil price; the impact of increasing competition; conditions in general economic and financial markets; availability of drilling and related equipment; effects of regulation by governmental agencies; receipt of partner, regulatory and community approvals; royalty rates; future operating costs; uninterrupted access to areas of Parex’s operations and infrastructure; recoverability of reserves and future production rates; the status of litigation; timing of drilling and completion of wells; on-stream timing of production from successful exploration wells; operational performance of non-operated producing fields; pipeline capacity; that Parex will have sufficient cash flow, debt or equity sources or other financial resources required to fund its capital and operating expenditures and requirements as needed; that Parex’s conduct and results of operations will be consistent with its expectations; that Parex will have the ability to develop its oil and gas properties in the manner currently contemplated; that Parex’s evaluation of its existing portfolio of development and exploration opportunities is consistent with its expectations; current or, where applicable, proposed industry conditions, laws and regulations will continue in effect or as anticipated as described herein; that the estimates of Parex’s production and reserves volumes and the assumptions related thereto (including commodity prices and development costs) are accurate in all material respects; that Parex will be able to obtain contract extensions or fulfill the contractual obligations required to retain its rights to explore, develop and exploit any of its undeveloped properties; that Parex will have sufficient financial resources to pay dividends and acquire shares pursuant to its NCIB in the future; that Parex is able to execute its plans with respect to the Company’s drilling program as disclosed herein; and other matters.

    Management has included the above summary of assumptions and risks related to forward-looking information provided in this document in order to provide shareholders with a more complete perspective on Parex’s current and future operations and such information may not be appropriate for other purposes. Parex’s actual results, performance or achievement could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits Parex will derive. These forward-looking statements are made as of the date of this document and Parex disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

    This press release contains information that may be considered a financial outlook under applicable securities laws about the Company’s potential financial position, including, but not limited to; Parex’s FY 2025 capital expenditure guidance; Parex 2025 guidance, including anticipated Brent crude oil average prices, funds flow provided by operations netback; funds flow provided by operations, capital expenditures, free funds flow; and the anticipated terms of the Company’s Q2 2025 regular quarterly dividend including its expectation that it will be designated as an “eligible dividend”, all of which are subject to numerous assumptions, risk factors, limitations and qualifications, including those set forth in the above paragraphs. The actual results of operations of the Company and the resulting financial results will vary from the amounts set forth in this press release and such variations may be material. This information has been provided for illustration only and with respect to future periods are based on budgets and forecasts that are speculative and are subject to a variety of contingencies and may not be appropriate for other purposes. Accordingly, these estimates are not to be relied upon as indicative of future results. Except as required by applicable securities laws, the Company undertakes no obligation to update such financial outlook. The financial outlook contained in this press release was made as of the date of this press release and was provided for the purpose of providing further information about the Company’s potential future business operations. Readers are cautioned that the financial outlook contained in this press release is not conclusive and is subject to change.

    The following abbreviations used in this press release have the meanings set forth below:

    bbl one barrel
    bbls barrels
    bbl/d barrels per day
    boe barrels of oil equivalent of natural gas; one barrel of oil or natural gas liquids for six thousand cubic feet of natural gas
    boe/d barrels of oil equivalent of natural gas per day
    mcf thousand cubic feet
    mcf/d thousand cubic feet per day
    W.I. working interest

    PDF available: http://ml.globenewswire.com/Resource/Download/974163af-5043-41d6-a129-53a272c53539

    The MIL Network –

    May 9, 2025
  • MIL-OSI: StepStone Group to Announce Fourth Quarter and Fiscal 2025 Results on May 22, 2025

    Source: GlobeNewswire (MIL-OSI)

    NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP) today announced that the Company will release its results for the fourth quarter and fiscal year ended March 31, 2025, after the market closes on Thursday, May 22, 2025.

    Webcast and Earnings Conference Call

    Management will host a webcast and conference call on Thursday, May 22, 2025, at 5:00 pm ET to discuss the Company’s results for the fourth quarter and fiscal year ended March 31, 2025. The webcast will be made available on the Shareholders section of the Company’s website at https://shareholders.stepstonegroup.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register. A replay will also be available on the shareholders website approximately two hours after the conclusion of the event.

    To join as a live participant in the question and answer portion of the call, participants must register at https://register-conf.media-server.com/register/BI83b497f55a944def8cfadab7f935822b.

    Upon registering you will receive the dial-in number and a PIN to join the call as well as an email confirmation with the details.

    About StepStone

    StepStone Group Inc. (Nasdaq: STEP) is a global private markets investment firm focused on providing customized investment solutions and advisory and data services to its clients. As of December 31, 2024, StepStone was responsible for approximately $698 billion of total capital, including $179 billion of assets under management. StepStone’s clients include some of the world’s largest public and private defined benefit and defined contribution pension funds, sovereign wealth funds and insurance companies, as well as prominent endowments, foundations, family offices and private wealth clients, which include high-net-worth and mass affluent individuals. StepStone partners with its clients to develop and build private markets portfolios designed to meet their specific objectives across the private equity, infrastructure, private debt and real estate asset classes.

    Contacts

    Shareholder Relations:
    Seth Weiss
    shareholders@stepstonegroup.com
    1-212-351-6106

    Media:
    Brian Ruby / Chris Gillick / Matt Lettiero, ICR
    StepStonePR@icrinc.com
    1-203-682-8268

    The MIL Network –

    May 9, 2025
  • MIL-OSI Economics: RBI imposes monetary penalty on Shree Warana Sahakari Bank Limited, Warananagar, Maharashtra

    Source: Reserve Bank of India

    The Reserve Bank of India (RBI) has, by an order dated May 05, 2025, imposed a monetary penalty of ₹2.00 lakh (Rupees Two Lakh only) on Shree Warana Sahakari Bank Limited, Warananagar, Maharashtra (the bank) for contravention of the provisions of Section 26A read with Section 56 of the Banking Regulation Act, 1949 (BR Act). This penalty has been imposed in exercise of powers conferred on RBI under the provisions of Section 47A(1)(c) read with Sections 46(4)(i) and 56 of the BR Act.

    The statutory inspection of the bank was conducted by RBI with reference to its financial position as on March 31, 2024. Based on supervisory findings of contravention of statutory provisions and related correspondence in that regard, a notice was issued to the bank advising it to show cause as to why penalty should not be imposed on it for its failure to comply with the said statutory provisions. After considering the bank’s reply to the notice, RBI found, inter alia, that the following charge against the bank was sustained, warranting imposition of monetary penalty:

    The bank had failed to transfer eligible unclaimed amounts to the Depositor Education and Awareness Fund within the prescribed time.

    This action is based on deficiencies in statutory compliance and is not intended to pronounce upon the validity of any transaction or agreement entered into by the bank with its customers. Further, imposition of monetary penalty is without prejudice to any other action that may be initiated by RBI against the bank.

    (Puneet Pancholy)  
    Chief General Manager

    Press Release: 2025-2026/284

    MIL OSI Economics –

    May 9, 2025
  • MIL-OSI: Sky Quarry Signs LOI with R & R Solutions to Explore Expansion of Southwest Operations and Accelerate Market Deployment

    Source: GlobeNewswire (MIL-OSI)

    WOODS CROSS, Utah, May 08, 2025 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or “the Company”), an integrated energy solutions company committed to revolutionizing the waste asphalt shingle recycling industry, today announced that it has signed a non-binding Letter of Intent (LOI) with R & R Solutions Inc., the only permitted asphalt shingle recycler in New Mexico. The LOI represents a strategic step in Sky Quarry’s plan to expand its national network of modular waste-to-energy facilities and unlock new revenue opportunities in the Southwest.

    The proposed partnership will focus on planning the deployment of Sky Quarry’s proprietary equipment, mechanical processes, and intellectual property (IP) at R & R Solutions’ existing permitted site in Albuquerque, New Mexico. If implemented, the proposed project will support the production of high-value byproducts, including asphalt-coated limestone, sand, granules, bitumen, and structural-grade ground shingles for use in roofing, road repair, sealants, and other infrastructure applications.

    As part of Sky Quarry’s differentiated business model, the Company expects to generate revenue both from accepting asphalt shingle waste and from selling the recovered byproducts. At the proposed New Mexico site, Sky Quarry estimates that approximately 100,000 tons of asphalt shingle waste could be processed per year and believes that this could generate substantial annual revenue from collection fees and the sale of recycled materials such as granules and sand. The Company also believes that the feedstock could yield the equivalent of up to 150,000 barrels of oil when fully refined, representing additional potential revenue.

    “The opportunity to collaborate with R & R Solutions and build on an existing permitted site creates an attractive entry point for strengthening our national scale-up efforts and advancing commercialization,” said David Sealock, CEO and Chairman of Sky Quarry. “The Albuquerque region presents a particularly compelling opportunity due to its proximity to our PR Spring facility in Utah, which will serve as a regional hub for hydrocarbon extraction. Upon reaching an agreement with R&R Solutions based on the LOI, we believe that leveraging existing infrastructure and integrating operations across both sites will accelerate deployment, reduce capital intensity, and improve supply chain logistics for recovered oil products, efficiencies that we believe will drive stronger margins and long-term value.”

    Founded in 2013, R & R Solutions brings over a decade of experience as a leader in responsible recycling practices and is deeply integrated into the New Mexico construction ecosystem. “The proposed partnership with Sky Quarry will mark a strategic step forward for R & R Solutions,” said Jerry Daniele, Vice President of R & R Solutions. “We’ve built a strong foundation as the region’s only permitted shingle recycler, and we believe that this collaboration will give us the tools to expand our capabilities, accelerate growth, and deliver broader impact. It will allow us to scale the value we provide to customers and communities across New Mexico and move beyond traditional recycling into large-scale resource recovery, driving meaningful economic impact in the region.”

    About Sky Quarry Inc.

    Sky Quarry Inc. (NASDAQ:SKYQ) and its subsidiaries are, collectively, an oil production, refining, and a development-stage environmental remediation company formed to deploy technologies to facilitate the recycling of waste asphalt shingles and remediation of oil-saturated sands and soils. Our waste-to-energy mission is to repurpose and upcycle millions of tons of asphalt shingle waste, diverting them from landfills. By doing so, we can contribute to improved waste management, promote resource efficiency, conserve natural resources, and reduce environmental impact. For more information, please visit skyquarry.com.

    Forward-Looking Statements

    This press release may include ”forward-looking statements.” All statements pertaining to our future financial and/or operating results, future events, or future developments may constitute forward-looking statements. The statements may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project,” or words of similar meaning. Such statements are based on the current expectations and certain assumptions of our management, of which many are beyond our control. These are subject to a number of risks, uncertainties, and factors, including but not limited to those described in our disclosures. Should one or more of these risks or uncertainties materialize or should underlying expectations not occur or assumptions prove incorrect, actual results, performance, or our achievements may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. We neither intend, nor assume any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated. You are urged to carefully review and consider any cautionary statements and the Company’s other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Company’s Form 10-K as filed with the SEC on March 31, 2025. Forward-looking statements speak only as of the date of the document in which they are contained.

    Investor Relations
    Jennifer Standley
    Director of Investor Relations
    Ir@skyquarry.com

    Company Website
    www.skyquarry.com

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Stack Capital Group Inc. Reports Q1-2025 Financial Results

    Source: GlobeNewswire (MIL-OSI)

    TORONTO, May 08, 2025 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A) today announced its financial results for the quarter ended March 31, 2025. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated.

    Company Commentary:

    • As at March 31, 2025, Book Value per Share (BVpS) of the Company was $12.06, compared with $12.29 as at December 31, 2024.
    • Stack Capital had its first portfolio investment, CoreWeave (an AI hyper-scaler) go public on March 28, 2025, an exciting milestone for both the Company and CoreWeave. During the quarter, and prior to the IPO, Stack invested an additional US$2.2 million into CoreWeave.
    • As of March 31, 2025, the Company wrote down its investment in CoreWeave by US$2.4 million to reflect its closing price of US$37.08. Since then, however, CoreWeave’s share price has increased to US$53.60 (as of close on May 7, 2025), representing a 45% gain from March 31, 2025, equating to an estimated $0.45 increase to Stack Capital’s BVpS since quarter end. The Company believes that CoreWeave’s share price has the potential to increase over the next several months as it reports its initial quarterly results, announces potential new business deals, and general market sentiment improves with anticipated resolutions to global trade/tariffs and other geo-political issues.
    • During Q1, Shield AI raised US$240 million at a US$5.3 billion valuation, resulting in an increase to the position value within the portfolio. Shield AI also recently announced significant strategic partnerships with both Boeing (March 2025) and Airbus U.S. Space & Defense (April 2025). Shield AI’s Hivemind solution will be used to improve and expand unmanned capabilities across the aerial programs at both companies, serving to further validate Shield AI’s leadership position in AI pilot technology.
    • Following quarter-end, SpaceX received approval from the Federal Aviation Administration (FAA) to increase the number of its Starship launches to 25 times per year, up from 5 times per annum under its previous license. This increase in launch cadence for future Starship test flights is significant and will eventually benefit Starlink (SpaceX’ satellite communications business) through the faster deployment of its next generation satellites, once Starship becomes fully operational.
    • In March, Locus Robotics unveiled its brand new ‘Array’ autonomous mobile robot at LogiMat in Stuttgart, Germany, and at ProMat in Chicago. As the industry’s most advanced AI-powered, zero-touch fulfillment system, Array eliminates 90% of manual labour for picking, putaway, and returns of merchandise within warehouse and third-party logistics facilities. Leveraging the latest advances in AI vision technology, Array delivers ultra-efficient order picking, unmatched cost per pick, along with the unique ability to pick and consolidate multiple orders simultaneously.
    • Following quarter-end, Omio, a leading multi-modal travel booking platform, announced its expansion into Southeast Asia, unlocking over 14,000 bus routes from over 1,800 transportation providers across Singapore, Vietnam, Thailand, Malaysia, Indonesia, and Cambodia, adding to its existing flight options in the region. Omio also plans to add ferry and rail services over the coming months and is aiming to be a comprehensive multi-modal travel provider by Q4-2025, in time for peak season of Southeast Asian travel. Following the announcement, the Omio app now unifies transportation across 3 continents and 45 countries.
    • As at March 31, 2025, the Book Value of the Company was $129.7 million, and the Book Value per Share was $12.06. A detailed summary of Book Value per Share is as follows:
    Breakdown of Book Value per Share as at March 31, 2025:  
    SpaceXi(space exploration & satellite communications) $ 2.18  
    Locus Robotics, Inc. (autonomous robots)   1.32  
    Canva, Inc. (graphic design)   1.29  
    Omio, Inc.ii(travel & leisure)   1.11  
    Hopper, Inc. (travel & leisure)   1.07  
    Newfront Insurance, Inc. (insurance & benefits)   1.07  
    Prove Identity, Inc.iii(cyber-security)   1.02  
    CoreWeave, Inc. (AI hyper-scaler)   1.01  
    Bolt Financial, Inc. (e-commerce)   0.50  
    Shield AI, Inc.iv(military defence)   0.39  
    Varo Money, Inc. (neo-banking)   0.13  
    Cash   1.00  
    Net other assets   (0.03 )
    Book Value per Share $ 12.06  

    i the Company is invested in Space Exploration Technologies Corp. (“SpaceX”) through a Special Purpose Vehicle, Space LP.
    ii the Company invested in shares of GoEuro Corp. which carries on business as Omio.
    iii the fair value of Prove Identity Inc. includes an unrealized deferred gain of $1,021,025
    iv the Company is invested in Shield AI through a Special Purpose Vehicle, Defence AI LP

    About Stack Capital

    Stack Capital is an investment holding company and its business objective is to invest in equity, debt and/or other securities of growth-to-late-stage private businesses. Through Stack Capital, shareholders have the opportunity to gain exposure to a diversified private investment portfolio; participate in the private market; and have liquidity due to the listing of the Common Shares & Warrants on the TSX. At the same time, the public structure also allows the Company to focus its efforts on maximizing long-term performance through a portfolio of high growth businesses, which are not widely available to most Canadian investors. SC Partners Ltd. acts as the Company’s administrator and is responsible to source and advise with respect to all investments for the Company.

    For more information, please visit our website at www.stackcapitalgroup.com or contact:
    Brian Viveiros
    VP, Corporate Development, and Investor Relations
    647.280.3307
    brian@stackcapitalgroup.com

    Non-IFRS Financial Measures

    This press release may make reference to the following financial measures which are not recognized under International Financial Reporting Standards (“IFRS”), and which do not have a standard meaning prescribed by IFRS:

    • Book Value – the aggregate fair value of the assets of the Company on the referenced date, less the aggregate carrying value of the liabilities, excluding any deferred taxes or unrealized deferred gains or losses if applicable, of the Company; and
    • Book Value per Share (BVpS) – the Book Value on the referenced day divided by the aggregate number of Common Shares that are outstanding on such day.

    The Company’s Book Value and Book Value per Share is a measure of the performance of the Company as a whole. The Company’s method of determining this financial measure may differ from other issuers’ methods and, accordingly, this amount may not be comparable to measures used by other issuers. This financial measure is not a performance measure as defined under IFRS and should not be considered either in isolation of, or as a substitute for, net earnings per share prepared in accordance with IFRS.

    Cautionary Note Regarding Forward-Looking Information

    This press release contains forward-looking information. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as “proposed”, “expects”, “intends”, “may”, “will”, and similar expressions. Forward-looking information contained or referred to in this press release includes but may not be limited to the business of Stack Capital and the risks associated therewith, including those identified in the Annual Information Filing under the heading “Risk Factors”.

    Forward-looking statements or information are based on a number of factors and assumptions which have been used to develop such statements and information, but which may prove to be incorrect. Although Stack Capital believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because Stack Capital can give no assurance that such expectations will prove to be correct. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to, the ability to capitalize on investment opportunities. The forward-looking information in this press release reflects the current expectations, assumptions and/or beliefs of Stack Capital based on information currently available to Stack Capital.

    Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Stack Capital disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events, or results or otherwise. The forward-looking statements or information contained in this press release are expressly qualified by this cautionary statement.

    The MIL Network –

    May 9, 2025
  • MIL-OSI Economics: [Exploring Good Lock ③] Three Features Recommended by Samsung Developers & Newsroom Editors

    Source: Samsung

    Parts one and two of this series explored Good Lock, Samsung Electronics’ user interface (UI) customisation app developed for Galaxy devices — highlighting the platform’s evolution with the One UI 7 update, from the redesigned Home Up module to the top three most-used tools.
     
    In this final instalment, Samsung Newsroom editors and the Good Lock development team put the spotlight on some of the standout features.
     
    Wonderland: Dynamic Customisation for Lock and Home Screens
    Wonderland enables users to create animated wallpapers for the lock and home screens — bringing a vibrant, dynamic aesthetic to the first screens encountered when the device is turned on. Previously, the same wallpaper had to be applied to both the lock and home screens. However, in response to user feedback, each screen can now be customised independently for greater creative freedom.
     
    Users can layer various design elements — such as images, text, videos and particle effects 1 — and apply motion effects including left-right, up-down and front-back movement to create 3D wallpapers that respond dynamically to device tilt and touch.
     

    https://img.global.news.samsung.com/za/wp-content/uploads/2025/05/Samsung-Mobile-Good-Lock-Home-Up-Developers-and-Editors-Picks-Wonderland-Edge-Lighting-and-Nice-Shot_main1-1.mp4

    ▲ Wonderland
     

    https://img.global.news.samsung.com/za/wp-content/uploads/2025/05/SamsungMobileGood_LockHome_UpDevelopers_and_Editors_PicksWonderland_Edge_Lighting_and_Nice_Shot_main2_595809.mp4

    ▲ A wallpaper created using Wonderland
     
    Moreover, users can personalise the transition effects between the Always On Display (AOD) and the lock screen to add a stylish touch to their device’s first impression. Detailed controls over transition speed and depth allow for playful effects, such as stickers that appear and disappear over an image.
     
    As one of Good Lock’s defining features, Wonderland combines creativity with the satisfaction of a visually immersive experience.
     

    https://img.global.news.samsung.com/za/wp-content/uploads/2025/05/SamsungMobileGood_LockHome_UpDevelopers_and_Editors_PicksWonderland_Edge_Lighting_and_Nice_Shot_main3_595811-1.mp4

    ▲ Customised transitions between the AOD and the lock screen
    Edge Lighting+: Customised Notifications That Catch the Eye
    Edge lighting+ transforms everyday notifications into eye-catching visuals — adding a personalised touch to every alert that appears on the screen. Through the Set Custom Style menu, users can fully customise the image, colour and animation that accompany incoming notifications. Beyond default images, stickers created on Galaxy devices can be applied to give each notification a unique and personal touch.
     

    https://img.global.news.samsung.com/za/wp-content/uploads/2025/05/SamsungMobileGood_LockHome_UpDevelopers_and_Editors_PicksWonderland_Edge_Lighting_and_Nice_Shot_main4_595813.mp4

    ▲ Edge lighting+
     
    The Style by keyword menu allows users to assign specific effects to notifications containing certain keywords — ensuring that important messages stand out. For example, terms like “boss,” “report” or “meeting” can trigger distinct visuals for relevant notifications.
     

    https://img.global.news.samsung.com/za/wp-content/uploads/2025/05/Samsung-Mobile-Good-Lock-Home-Up-Developers-and-Editors-Picks-Wonderland-Edge-Lighting-and-Nice-Shot_main5-1.mp4

    ▲ Style by keyword
     
    Additional customisation options include changing the notification image to appear as an app icon or activating effects only when the screen is off. Despite its wide range of features, Edge lighting+ makes it easy for users to create stylish, personalised notifications with minimal effort.
     
    Nice Shot: Effortless Screenshot Management
    Nice Shot streamlines screenshot management — making it easy to capture, delete and organise images the moment they appear on screen. A delete button appears immediately after taking a screenshot – allowing users to remove images they don’t need without opening the Gallery app.
     

    ▲ Deleting an unwanted screenshot using Nice Shot
     
    Furthermore, users can configure their device to automatically enable Do Not Disturb mode during screen recordings to prevent interruptions from notifications or messages. As one of Good Lock’s most practical enhancements, Nice Shot adds everyday convenience to Galaxy devices.
     
    The diverse Good Lock features showcased throughout this series reflect the thoughtful collaboration between Galaxy users seeking a truly personalised experience and the Samsung developers dedicated to making that vision a reality. By delivering greater convenience and deeper customisation, Good Lock continues to evolve in step with the needs of its users and the creativity of its developers — and this is just the beginning
     

     

     
    1 Visual effects in Wonderland such as flying snowflakes, scattered raindrops, rising bubbles, twinkling stars and fluttering petals.

    MIL OSI Economics –

    May 9, 2025
  • MIL-OSI Economics: US anesthesia and respiratory devices market faces disruption as tariffs drive supply chain shift, says GlobalData

    Source: GlobalData

    US anesthesia and respiratory devices market faces disruption as tariffs drive supply chain shift, says GlobalData

    Posted in Medical Devices

    The US anesthesia and respiratory (A&R) devices market faces major disruption as new US tariffs hit foreign-made products, with majority of all 510(k) approved devices manufactured outside the country. This raises serious supply chain concerns and may shift market dynamics in favor of domestic manufacturers, even as the market grows from $4.4 billion in 2023 to a projected $7.5 billion in 2033, according to GlobalData, a leading data and analytics company.

    An analysis of GlobalData’s Medsource Database reveals that an estimated 67% of all 510(k) approved A&R devices are manufactured outside the US while 54% of those are manufactured solely outside the US.

    Aidan Robertson, Medical Analyst at GlobalData, comments: “A&R may be especially susceptible to changes in trade policies as a significant portion of the products are manufactured outside the US. This may cause issues in how effectively these devices can be provided to the relevant patient population.”

    GlobalData attributes the US anesthesia and respiratory devices market growth to an aging population which in turn is increasing the prevalence of respiratory related illnesses as well as advancements in technology relating to A&R.

    Robertson continues: “Some barriers to the growth include the higher costs of newer anesthesia and respiratory devices, which can limit accessibility. More recently, the ongoing trade war has emerged as a key challenge, discouraging product development, disrupting medical device supply chains, and increasing costs for consumers.”

    With US tariffs on China still at 145%, the impact is significant on the estimated 17% of 510(k) approved anesthesia and respiratory products made in China, especially the 10% manufactured exclusively there.

    Robertson concludes: “Companies facing greater financial risk, such as Respironics, may consider shifting more production to the US. However, this can lead to significant short-term revenue losses, benefiting competitors with stronger domestic manufacturing operations. As a result, the US anesthesia and respiratory market may see a shift in market share as healthcare providers turn to suppliers better positioned to navigate the tariffs.”

    MIL OSI Economics –

    May 9, 2025
  • MIL-OSI Economics: India and Japan drive revenue growth among top 20 APAC banks as Chinese giants slow down, reveals GlobalData

    Source: GlobalData

    India and Japan drive revenue growth among top 20 APAC banks as Chinese giants slow down, reveals GlobalData

    Posted in Business Fundamentals

    The top 20 Asia-Pacific (APAC) banks saw a modest 6.5% increase in combined revenue from $1.6 trillion in 2023 to $1.75 trillion in 2024, driven by exceptional growth from Indian and Japanese banks. On the other hand, several Chinese banks faced stagnation or declines amid tighter regulations and slowing credit demand. This shift highlights evolving regional dynamics and signals changing leadership in APAC’s banking landscape, reveals GlobalData, a leading data and analytics company.

    Murthy Grandhi, Company Profiles Analyst at GlobalData, comments: “APAC banking landscape witnessed a striking shift in momentum in 2024, as Indian and Japanese banks delivered powerful revenue growth, some of the China’s traditionally dominant institutions recorded either marginal gains or outright declines. It also reveals not just a reshuffling of leaders, but also deeper structural signals driven by macroeconomic realignments, domestic policy shifts, and evolving capital flows.”

    Only three banks achieved revenue growth exceeding 40% in 2024: India’s HDFC Bank led with an impressive 89.5% year-on-year (YoY) increase, while Japan’s Sumitomo Mitsui Financial and Mizuho Financial followed with growth rates of 42.8% and 41.6%, respectively

    Grandhi explains: “HDFC Bank’s rise can be attributed to its merger with HDFC Ltd., robust retail lending growth, and digital banking expansion. Likewise, State Bank of India recorded a 19.4% jump to $72 billion, fueled by rising credit demand in infrastructure, manufacturing, and rural segments.

    “Japanese banks staged a strong comeback after years of modest performance. This surge is underpinned by enhanced cross-border M&A advisory, corporate lending in Southeast Asia, and increased activity in the green finance space.”

    Japan-based Mitsubishi UFJ Financial posted an 11.7% increase to $81.7 billion, reflecting stronger domestic lending and strategic international acquisitions.

    Chinese banks continued to dominate the revenue leaderboard, securing 11 of the top 20 positions. ICBC led with $227.9 billion in revenue, though it posted a slight YoY contraction of -0.6%. Similarly, China Construction Bank ($198.1 billion, -2%), Postal Savings Bank of China ($81.7 billion, -0.7%), and Shanghai Pudong Development Bank ($49.2 billion, -4.4%) reflected a slowdown. The declines stem from reduced credit demand, property sector headwinds, and the cautious lending stance amid tighter regulatory controls.

    Nevertheless, Bank of China showed resilience with a 2.6% increase in revenue to $177.6 billion, supported by strong offshore financing operations and currency settlements, benefiting from the yuan’s expanding role in trade settlements.

    Grandhi concludes: “As the global financial system braces for a volatile 2025, APAC banks are navigating a complex matrix of geopolitical tensions, tariff escalations, and tightening liquidity. The US-China trade recalibration, semiconductor export restrictions, and ongoing regional disputes could dampen cross-border capital flows and increase regulatory compliance costs.

    “However, banks with strong domestic franchises, digital agility, and diversified international exposure, especially in India, Japan, and Australia, are better positioned to weather uncertainty and tap into structural growth trends, including fintech adoption, infrastructure financing, and ESG-related lending. The year ahead will test these institutions not just on balance sheet strength but on their ability to adapt strategically in an evolving global order.”

    MIL OSI Economics –

    May 9, 2025
  • MIL-OSI Global: Alberta has long accused Ottawa of trying to destroy its oil industry. That’s a dangerous myth

    Source: The Conversation – Canada – By Ian Urquhart, Professor Emeritus, Political Science, University of Alberta

    “Alberta is a place soaked in self-deception.” Those words began Alberta-based journalist Mark Lisac’s 2004 book aimed at shattering the myths that have unhelpfully animated too much of Alberta’s politics over the past few decades.

    Current and former Alberta politicians are once again embracing and treating separatist grievances seriously. That means it’s time once again to highlight and challenge political misconceptions that have the potential to destroy Canada.

    Oil is the root of one such myth. The misconception? That Ottawa perenially opposes the oil and gas sector and is determined to stop its continued growth. The National Energy Program (1980), the Northern Gateway pipeline project (2016), the Energy East Pipeline (2017) and the proposed greenhouse gas pollution cap allegedly prove Ottawa’s hostility.

    Notably missing from these grievances is the Keystone XL pipeline and the Trans Mountain Expansion Project. Ottawa supported these projects aimed at transporting Alberta oilsands crude to foreign markets. The federal government even purchased the Trans Mountain project from Kinder Morgan in 2018 — not to kill it, but to build it.




    Read more:
    Justin Trudeau’s risky gamble on the Trans Mountain pipeline


    As for Keystone XL, Alberta Premier Jason Kenney thanked Prime Minister Justin Trudeau for supporting the project. This doesn’t fit the separatist narrative, so it’s largely ignored.

    Oilsands booster

    No one should dispute the National Energy Program’s devastating impact on Alberta’s conventional oil and gas sector 40 years ago. But the oilsands, not conventional oil, propelled Canada to its position as the world’s fourth largest oil producer.

    Has Ottawa facilitated or obstructed the spectacular post-1990 growth of oilsands production?

    The record shows that, since the mid-1970s, Ottawa has facilitated and supported the oilsands sector. The federal government helped keep the Syncrude project alive in 1975 when it took a 15 per cent interest in Canada’s second oilsands operation.

    Ironically, Ottawa’s enthusiasm for more, not less, petroleum from the oilsands also appeared in 1980 via the National Energy Program (NEP), the devil in Alberta’s conservative catechism. What most accounts of the NEP don’t mention is that Ottawa offered tax benefits to oilsands companies while stripping them from conventional oil producers.

    Furthermore, the NEP’s “made-in-Canada” pricing effectively guaranteed Syncrude would receive the world price for its production. At $38 per barrel, Syncrude received more than double what conventional producers received. If the NEP was harsh on conventional oil producers, it helped create a golden future for the oil sands.

    In the mid-1990s, Ottawa helped propel the post-1995 oilsands boom. The industry-dominated National Task Force on Oil Sands Strategies sought federal tax concessions to promote oilsands growth. The federal government delivered them in its 1996 budget, despite Prime Minister Jean Chretien’s general concern with cutting the deficit.

    Again, these measures clearly contradict the myth of federal opposition to the oil industry.

    Generous emissions caps

    Ottawa’s policy favouritism towards the oilsands didn’t end there. It has consistently animated the federal government’s treatment of the oilsands in its climate change policies.

    The federal Climate Change Plan for Canada (2002) treated oil and gas leniently. Its measures for large industrial emitters bore a striking resemblance to the climate change policy preferences of the Canadian Association of Petroleum Producers. Suncor and Syncrude, the two leading oilsands producers, estimated these federal proposals would add a pittance, between 20 and 30 cents, to their per barrel production costs.

    Justin Trudeau’s response to Alberta’s 2015 oilsands emissions cap also underlined Ottawa’s favouritism, not hostility, to the dominant player in Canada’s oil patch.

    Rachel Notley’s NDP government set this cap at 100 million tonnes of GHG per year, plus another 10 million tonnes allowed to new upgrading and co-generation facilities. This cap was a whopping 39 million tonnes or 55 per cent higher than what the oilsands emitted in 2014.

    This generous cap contributed to a tremendous increase in oilsands production. Healthy profits became record profits in 2022. Ottawa embraced Alberta’s largesse, incorporating the province’s cap into its post-2015 climate policies.

    Furthermore, Ottawa increased its leniency towards the oilsands by exempting new in-situ (non-mining) oilsands projects in Alberta from the federal Impact Assessment Act. This exemption applies until Alberta’s emissions cap is reached. Canada’s latest National Inventory Report on greenhouse gas emissions reported record oilsands GHG emissions of 89 million tonnes in 2023, still 11 million tonnes shy of the 100 million tonne threshold.

    Weaponizing myths

    Finally, we have today’s proposed national cap on greenhouse gas emissions. Alberta is apoplectic about the cap. But whether or not it’s intentional, Premier Danielle Smith’s outrage feeds into secessionist sentiment by seemingly misrepresenting the cap’s impact on oil and gas production.

    Smith and her environment minister use the work of the Parliamentary Budgetary Officer (PBO) to nurture their “Ottawa hates oil” narrative. They claim the officer’s analysis of the cap’s economic impact showed it “will cut oil and gas production by five per cent, or more than 245,000 barrels per day.”

    This is simply not true.

    In fact, the PBO concluded that, with the cap, oilsands production “is projected to remain well above current levels” — 15 per cent higher than in 2022. The proposed federal emissions cap, like the Alberta NDP’s cap of a decade ago, is higher than current oilsands emissions levels. The PBO concluded the proposed ceiling for oilsands emissions would be six per cent higher than 2022 emissions.

    Ottawa’s proposed cap, in fact, continues its decades-long support of the oilsands.

    Myths are central to our being. When I tell my grandsons about the pot of gold at the end of the rainbow, I hope to inspire curiosity, imagination and interest in their grandmother’s Irish heritage.

    But in politics, fanciful stories can be dangerous. Some weaponize myths, using the fictions at their core to encourage followers to let falsehoods rule their behaviour. That seems to be playing out yet again in Alberta. We must demand better from the political class.

    Ian Urquhart does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    – ref. Alberta has long accused Ottawa of trying to destroy its oil industry. That’s a dangerous myth – https://theconversation.com/alberta-has-long-accused-ottawa-of-trying-to-destroy-its-oil-industry-thats-a-dangerous-myth-255908

    MIL OSI – Global Reports –

    May 9, 2025
  • MIL-OSI Asia-Pac: HK hosts 6G summit

    Source: Hong Kong Information Services

    The 6G Global Summit opened in Hong Kong today, marking the first time for the summit to be held in the Asia-Pacific region.

    The two-day summit is being hosted by the Communications Authority and has attracted hundreds of representatives of regulatory bodies, telecommunications operators and corporations from more than 80 countries to explore the potential of sixth-generation (6G) mobile communications technology in shaping the future.

    In his keynote speech, Secretary for Commerce & Economic Development Algernon Yau said that Hong Kong is uniquely positioned to play a leading role in 6G development, with the Government committed to fostering a conducive environment for technological advancement and preparing for the 6G era.

    He noted that major mobile network operators in the city have actively commenced testing and successfully validating the 5G-Advanced network in various applications such as large-scale drone shows, world class sports events and more.

    As regards the Government’s efforts in the relevant areas, Mr Yau said: “We are also proactively exploring further facilitation measures from a telecommunications perspective to support the development of a low-altitude economy.”

    He also pointed out that the Government is conducting a study to streamline relevant licensing procedures for Low Earth Orbit satellites.

    For his part, Director-General of Communications Chaucer Leung noted at the summit’s opening ceremony that Hong Kong is the first economy in the world to have auctioned a radio spectrum in the upper six gigahertz band.

    The spectrum is suitable for the provision of 5G services now and 6G services in the future, he said, adding that the first set of technical standards for 6G is expected to be finalised in 2029 so that a commercial service can be introduced in the following year.

    The summit features discussions on 6G developments, including standardisation, technological innovations, sustainability and potential applications as well as the strategic role of the Asia-Pacific region and the opportunities presented by a more connected and intelligent global network.

    First held in 2022, this is the summit’s fourth edition. The previous two editions were held in Bahrain in 2023 and the UK in 2024.

    MIL OSI Asia Pacific News –

    May 9, 2025
  • MIL-OSI United Kingdom: Court upholds CMA’s £99m fine on pharma over excessive NHS thyroid drug prices

    Source: United Kingdom – Government Statements

    Press release

    Court upholds CMA’s £99m fine on pharma over excessive NHS thyroid drug prices

    The Court of Appeal has unanimously upheld the CMA’s finding that Advanz broke the law by overcharging the NHS for essential thyroid drug liothyronine.

    • CMA secures important win in the Court of Appeal after Advanz and Cinven sought to appeal
    • Court of Appeal also reinstated the CMA’s original fine of £51.9 million on Cinven after the CAT reduced the figure to £37.1 million in 2023
    • Total amount in fines stands at £99 million, divided amongst Advanz’s owners across the infringement period: £6.2m for HgCapital; £51.9m for Cinven; and £40.9m for Advanz

    In a unanimous judgment, the Court of Appeal has confirmed the Competition and Markets Authority’s (CMA) finding of excessive and unfair pricing in the supply of liothyronine tablets in the UK; and has reinstated the full penalty of £51.9 million imposed by the CMA on private equity firm Cinven.

    Liothyronine is an essential medicine used to treat thyroid hormone deficiency. In 2006, the total NHS annual spend on the tablets was £600,000. Between 2009 and 2017, Advanz, the sole supplier of liothyronine tablets in the UK, increased the price it charged from £20 to £248 per box – an increase of over 1,110%. As a result, NHS annual spending on liothyronine jumped from over £2.3 million in 2009 to more than £30 million by 2016.

    After an extensive investigation, in July 2021, the CMA found that Advanz had broken the law by this level of pricing to the NHS, without justification: the cost of producing the tablets did not increase significantly; and there was no evidence of meaningful innovation or investment by the supplier. The CMA fined Advanz Pharma (the current owner of the Advanz business) together with two former owners (HgCapital and Cinven) for their part in the infringement over their ownership periods.  

    All three companies originally appealed the CMA’s decision before the Competition Appeal Tribunal (CAT). In August 2023, the CAT fully upheld the CMA’s findings, but reduced the penalties imposed on HgCapital and Cinven.

    HgCapital decided not to pursue its appeal further, instead agreeing with the CMA to pay its fine of £6.2 million. Advanz and Cinven both sought permission to appeal the CAT’s decision to the Court of Appeal and the CMA, in turn, sought to overturn the CAT’s reduction in Cinven’s penalty.

    Following a 3-day hearing in December 2024, the Court of Appeal unanimously refused Advanz Pharma and Cinven permission to appeal the CAT judgment, ruling that they had no arguable basis upon which to challenge the CAT’s decision to uphold the CMA’s findings.

    The Court of Appeal also agreed that the CMA’s original penalty for Cinven was appropriate and reinstated it in full to £51.9 million.

    Sarah Cardell, Chief Executive of the CMA, said:

    This is another resounding win for the CMA in this case – and a vote of confidence for the work we do to protect consumers and tackle illegal behaviour.

    Prices charged to the NHS, and ultimately taxpayers, must be fair. We will continue to stand up for patients and take action against companies that abuse their market power, thereby harming consumers and the wider economy.

    For more information on the CMA’s investigation, visit the Liothyronine tablets: suspected excessive and unfair pricing case page.

    Notes for editors:

    1. For media queries, please contact the press office on press@cma.gov.uk or on 020 3738 6460.
    2. Advanz Pharma and Cinven both appealed against the CAT’s judgment. The CMA cross-appealed against the CAT’s reduction of Cinven’s penalty from £51.9 million to £37.1 million.
    3. HgCapital did not appeal the CAT’s judgment.
    4. A three-day hearing took place in December 2024 to hear all parties’ appeals. The Court of Appeal had adjourned all applications for permission to appeal the CAT’s judgment into a ’rolled-up’ hearing of both those applications for permission and the substantive appeals.
    5. Previous action taken by the CMA in relation to the pharmaceutical sector and the fines imposed:
      •      Fludrocortisone (2019): £2.3 million in fines and £8 million redress to the NHS for market-sharing.
      •       Nortriptyline (2020): £3.4 million in fines and £1 million redress to the NHS for illegal arrangements including market-sharing and information exchange.
      •       Paroxetine (2021): £27.1 million in fines for anti-competitive agreements and abuse of dominance.
      •       Hydrocortisone (2021): £260 million in fines for excessive and unfair pricing and market sharing (currently under appeal).

    Share this page

    The following links open in a new tab

    • Share on Facebook (opens in new tab)
    • Share on Twitter (opens in new tab)

    Updates to this page

    Published 8 May 2025

    MIL OSI United Kingdom –

    May 9, 2025
  • MIL-OSI Russia: /Economic Review/ New Professions Fuel China’s Booming Cultural and Tourism Sector

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    Source: People’s Republic of China – State Council News

    CHANGCHUN, May 8 (Xinhua) — As dawn broke over Mount Taishan in east China’s Shandong Province, 26-year-old Wang Yang packed his backpack with essentials such as a first aid kit, trekking poles and sugar candies to replenish his energy.

    He is preparing to lead a family of five on a six-hour climb to the summit, his seventh tour group over the five-day May Day weekend that ended Monday.

    Wang Yang is part of a growing trend of “climbing guides” – people who keep company as they explore China’s scenic beauty spots. The new profession, which attracts students, mountaineering enthusiasts and guesthouse owners, offers personalized services such as route planning, photography and even “encouraging verbal therapy” to hikers along the way.

    Charging service fees ranging from 400 to 1,500 yuan (US$55 to US$208) depending on the difficulty of the route, some such guides manage to earn up to 30,000 yuan a month.

    The emergence of the new profession reflects a broader boom in tourism. For example, in the first quarter of 2025, Taishan was visited 1.27 million times, up 12.6 percent year-on-year. In 2023 and 2024, the mountain was visited more than 8 million times annually.

    “The move towards personalized and specialized services also reflects a significant increase in consumer demand,” said Wang Yang, who, thanks to his newfound knowledge of emergency medical care, was able to help revive a tourist suffering from hypoglycemia.

    About 1,000 kilometers away in northeast China’s Jilin Province, 50-year-old Yu Wei sat in a ski resort cabin, studying a thick stack of work notes. A technician by training, he played a key role in developing China’s first national standards for “ski patrol rescuers,” a newly recognized national profession.

    When Yu Wei entered the industry in 1995, China’s ski resorts relied on equipment donated by foreign countries and had few active holidaymakers. But that all changed after Beijing won the 2022 Winter Olympics in 2015, and ski visits to the country’s ski slopes increased to 234 million in 2024-25.

    “Now that 70 percent of skiers are snowboarding and trying difficult tricks, rescue work requires new skills,” said Yu Wei, whose team has developed protocols such as the “18-minute golden patrol cycle” to meet the changing demands of the sport.

    The emergence of new roles in the tourism industry, from food reviewers to sports technicians, reflects broader changes in society. Song Zhiqiang, a popular content creator from Yanbian Korean Autonomous Region (Jilin Province, northeast China), has turned food vlogging into a powerful marketing tool, increasing local sales and consumption by more than 10 million yuan. Industry data shows that social media influencers like Song Zhiqiang will help the country’s entrepreneurs earn 133.3 billion yuan in 2024.

    Since 2019, China has officially recognized 93 new occupations, with the total number of “new economy” workers reaching 84 million people, accounting for 21 percent of the country’s total workforce.

    “These occupations are not just jobs; they are indicators of rising consumption levels,” said Zhou Guangxu, an associate professor at the Institute of Labor Affairs at Renmin University of China. -0-

    MIL OSI Russia News –

    May 9, 2025
  • MIL-OSI Russia: Huawei to Unveil First HarmonyOS-Based PC Lineup on May 19

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    Source: People’s Republic of China – State Council News

    SHENZHEN, May 8 (Xinhua) — Chinese tech giant Huawei on Thursday said it will launch its first line of personal computers (PCs) based on its HarmonyOS operating system on May 19.

    The upcoming release marks a significant expansion of the HarmonyOS ecosystem across the smartphones and tablets it already supports.

    By launching computers equipped with the country’s first domestically produced operating system for the general public, Huawei is set to challenge the long-standing dominance of Microsoft Windows and Apple macOS in the personal computer market.

    Huawei’s HarmonyOS-based computers are one of the company’s R&D achievements over the past 5 years. Huawei emphasized that HarmonyOS includes robust security features, including a dedicated encryption security chip, secure access mechanisms, and encrypted data exchange.

    Huawei said the new computers will enable seamless interaction between Huawei-branded devices, allowing users to control and navigate between the screens of their phones, tablets and computers using a keyboard and mouse.

    HarmonyOS, or Hongmeng in Chinese, is an open-source operating system designed for a variety of devices and scenarios, including smart screens, tablets, wearables, and cars. It was first launched in August 2019.

    According to insiders, Huawei will have to put more effort into attracting users in the initial marketing phase, as the mainstream Windows and macOS operating systems offer a more mature and rich application ecosystem in the existing market.

    Huawei HarmonyOS-based computers support connectivity with over 1,000 external devices and currently have over 150 dedicated PC apps and over 300 ecosystem-compatible apps. -0-

    MIL OSI Russia News –

    May 9, 2025
  • MIL-OSI Russia: China’s Ministry of Commerce: China is ready to cooperate with all countries to promote healthy development of cross-border e-commerce

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    Source: People’s Republic of China – State Council News

    BEIJING, May 8 (Xinhua) — China is willing to work with all countries to strengthen cooperation and promote the healthy and sustainable development of cross-border e-commerce, Ministry of Commerce spokesperson He Yadong said at a regular press conference on Thursday.

    Cross-border e-commerce meets the individual needs of consumers around the world with advantages such as high efficiency, fast delivery and cost savings, the department official said.

    The comments came after the United States formally ended duty-free treatment for small packages from China on May 2.

    “Abolishing the duty-free treatment for small parcels from China will harm the interests of enterprises and consumers in both countries,” He Yadong said, adding that China firmly opposes it.

    He stressed that this move by the US will not change the trend of rapid development of cross-border e-commerce.

    China is willing to work with all countries to strengthen cooperation, jointly create a fair and predictable policy environment, and promote the healthy and sustainable development of cross-border e-commerce, the MOC spokesman said. -0-

    MIL OSI Russia News –

    May 9, 2025
  • MIL-OSI China: China ready to work with all countries on healthy cross-border e-commerce development: commerce ministry

    Source: People’s Republic of China – State Council News

    China ready to work with all countries on healthy cross-border e-commerce development: commerce ministry

    BEIJING, May 8 — China is willing to work with all countries to strengthen cooperation and promote the healthy and sustainable development of cross-border e-commerce, a spokesperson for the Ministry of Commerce said on Thursday.

    Cross-border e-commerce satisfies the personalized needs of consumers worldwide, boasting advantages such as high efficiency, fast delivery, and cost savings, said commerce ministry spokesperson He Yadong at a regular press conference.

    The remarks were made after the United States canceled its tariff exemption policy for small parcels from China on May 2.

    The cancellation will harm the interests of businesses and consumers in both countries, said the spokesperson, noting, “We firmly oppose it.”

    He emphasized that the U.S. policy move will not impede the rapid development momentum of cross-border e-commerce.

    China is willing to work with all countries to strengthen cooperation, jointly create a fair and predictable policy environment, and promote the healthy and sustainable development of cross-border e-commerce, according to the spokesperson.

    MIL OSI China News –

    May 8, 2025
  • MIL-OSI: Royalty Pharma Reports First Quarter 2025 Results

    Source: GlobeNewswire (MIL-OSI)

    • Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%
    • Net cash provided by operating activities of $596 million
    • Raised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million

    NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.

    “Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Guided by our dynamic capital allocation framework, we repurchased over $700 million of our Class A ordinary shares given our attractive outlook, we expanded our development-stage portfolio with an R&D funding partnership with Biogen and we again increased our quarterly dividend. Looking ahead, we have strong fundamental tailwinds underpinning our business with a robust deal pipeline and we remain on track to acquire our external manager in the second quarter. We plan to share further details on our attractive long-term outlook at our upcoming Investor Day in September.”

    Double-digit growth in Royalty Receipts and Portfolio Receipts

    • Royalty Receipts grew 12% to $788 million, primarily driven by strong performance from the cystic fibrosis franchise, Trelegy and Xtandi.
    • Portfolio Receipts increased by 17% to $839 million.

    Significant repurchase activity under recently announced $3 billion authorization

    • Repurchased 23 million Class A ordinary shares for $723 million guided by dynamic capital allocation framework.
    • Capital Deployment of $101 million; entered into Phase 3 R&D funding collaboration for Biogen’s litifilimab.
    • Increased quarterly dividend by approximately 5%.

    Positive clinical and regulatory updates across royalty portfolio

    • Johnson & Johnson’s Tremfya received FDA and EC approval in Crohn’s disease, EC approval in ulcerative colitis.
    • Positive Phase 3 results for Emalex’s ecopipam in Tourette syndrome.
    • Roche to initiate a Phase 3 program for trontinemab in Alzheimer’s disease later this year.

    Raised financial guidance for full year 2025 (excludes contribution from future transactions)

    • Royalty Pharma expects 2025 Portfolio Receipts to be between $2,975 million and $3,125 million, representing expected growth of 6% to 12%.
    • The company expects to update 2025 guidance for payments and operating and professional costs and interest paid after the closing of the internalization transaction, which is expected in the second quarter of 2025.

    Financial & Liquidity Summary

      Three Months Ended March 31,
      (unaudited)
    ($ and shares in millions) 2025 2024 Change
    Portfolio Receipts 839 717 17%
    Net cash provided by operating activities 596 665 (10)%
    Adjusted EBITDA (non-GAAP)* 738 656 12%
    Portfolio Cash Flow (non-GAAP)* 611 584 5%
    Weighted average Class A ordinary shares outstanding – diluted 578 597 (3)%

    *See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.

    Portfolio Receipts Highlights

          Three Months Ended March 31,
          (unaudited)
    ($ in millions)     2025 2024 Change
    Products: Marketers: Therapeutic Area:      
    Cystic fibrosis franchise Vertex Rare disease 250 218 14%
    Trelegy GSK Respiratory 85 71 21%
    Tysabri Biogen Neuroscience 61 69 (12)%
    Evrysdi Roche Rare disease 53 45 17%
    Xtandi Pfizer, Astellas Cancer 52 41 28%
    Imbruvica AbbVie, J&J Cancer 46 50 (8)%
    Promacta Novartis Hematology 44 43 4%
    Tremfya Johnson & Johnson Immunology 36 36 (1)%
    Cabometyx/Cometriq Exelixis, Ipsen, Takeda Cancer 21 18 16%
    Spinraza Biogen Rare disease 13 7 95%
    Trodelvy Gilead Cancer 13 10 23%
    Erleada Johnson & Johnson Cancer 11 9 21%
    Other products(5) 105 88 19%
    Royalty Receipts 788 705 12%
    Milestones and other contractual receipts 51 12 309%
    Portfolio Receipts 839 717 17%

    Amounts shown in the table may not add due to rounding.

    Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the cystic fibrosis franchise, Trelegy and Xtandi, as well as royalties from the 2024 launch of Voranigo.

    Portfolio Receipts was $839 million in the first quarter of 2025, an increase of 17% compared to $717 million in the first quarter of 2024, primarily driven by the same Royalty Receipts increases noted above and a milestone payment of $27 million related to Airsupra.

    Liquidity and Capital Resources

    Royalty Pharma’s liquidity and capital resources are summarized below:

    As of March 31, 2025, Royalty Pharma had cash and cash equivalents of $1.1 billion and total debt with principal value of $7.8 billion.

    In January 2025, Royalty Pharma completed the sale of the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with quarterly repayments received prior to the sale, resulted in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The proceeds provide added flexibility to pursue the company’s dynamic capital allocation strategy.

    In January 2025, Royalty Pharma announced a new share repurchase program under which it may repurchase up to $3.0 billion of its Class A ordinary shares. During the first quarter of 2025, Royalty Pharma repurchased approximately 23 million Class A ordinary shares for $723 million. During the first quarter of 2024, Royalty Pharma did not repurchase any Class A ordinary shares. The weighted-average number of diluted Class A ordinary shares outstanding for the first quarter of 2025 was 578 million as compared to 597 million for the first quarter of 2024.

    Liquidity Summary

      Three Months Ended March 31,
      (unaudited)
    ($ in millions) 2025   2024  
    Portfolio Receipts 839   717  
    Payments for operating and professional costs (102)   (61)  
    Adjusted EBITDA (non-GAAP) 738   656  
    Interest paid, net (127)   (73)  
    Portfolio Cash Flow (non-GAAP) 611   584  

    Amounts may not add due to rounding.

    • Adjusted EBITDA (non-GAAP) was $738 million in the first quarter of 2025. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs. Payments for operating and professional costs for the first quarter of 2025 included a $33 million one-time payment related to the management fee on the sale of the MorphoSys Development Funding Bonds.
    • Portfolio Cash Flow (non-GAAP) was $611 million in the first quarter of 2025. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.

    Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.

    Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $101 million in the first quarter of 2025, consisting primarily of the upfront research and development (“R&D”) funding for litifilimab (discussed further below) and a milestone payment related to Trelegy.

    In April 2025, Ferring Pharmaceuticals announced U.S. Food and Drug Administration (“FDA”) approval of a new manufacturing hub in Parsippany, NJ for Adstiladrin, its novel gene therapy for bladder cancer. The approval triggered a $200 million milestone payment that was paid in the second quarter of 2025 as part of the royalty agreement announced in 2023.

    The table below details Capital Deployment by category:

    Capital Deployment

      Three Months Ended March 31,
      (unaudited)
    ($ in millions) 2025   2024  
    Acquisitions of financial royalty assets (1)   (86)  
    Development-stage funding payments (51)   (1)  
    Milestone payments (50)   —  
    Investments in equity method investees —   (7)  
    Contributions from legacy non-controlling interests – R&D 0   0  
    Capital Deployment (101)   (93)  

    Amounts may not add due to rounding.

    Royalty Transactions

    In February 2025, Royalty Pharma entered into an R&D funding arrangement with Biogen to provide up to $250 million over six quarters, including $50 million upfront for the development of litifilimab. Litifilimab is in Phase 3 development for the treatment of lupus. The announced transaction amount reflects the entire amount of capital committed for new transactions during the year, including potential future milestones.

    The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com.

    Internalization Transaction

    In January 2025, Royalty Pharma agreed to acquire its external manager, RP Management, LLC (the “Manager”) (press release). This transaction to simplify Royalty Pharma’s corporate structure is expected to result in multiple benefits for shareholders. On a financial basis, the acquisition is expected to reduce costs and enhance economic returns on investments. Specifically, the acquisition will generate cash savings of greater than $100 million in 2026, rising to greater than $175 million in 2030 and driving cumulative savings of greater than $1.6 billion over ten years. The acquisition also increases shareholder alignment, enhances corporate governance, ensures management continuity and simplifies Royalty Pharma’s corporate structure.

    The total transaction value of approximately $1.1 billion(7) consists of approximately 24.5 million shares of Royalty Pharma equity that will vest over five to nine years, approximately $100 million in cash(8), and the assumption of $380 million of the Manager’s existing debt.

    The closing of the internalization transaction is subject to shareholders’ approval of the issuance of the share consideration and other customary closing conditions, including required regulatory approvals. The shareholder meeting will take place on May 12, 2025 and the transaction is estimated to close during the second quarter of 2025.

    Key Developments Relating to the Portfolio

    The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.

    Tremfya In May 2025, Johnson & Johnson announced that the European Commission (“EC”) approved Tremfya for the treatment of adult patients with moderately to severely active Crohn’s disease.

    In April 2025, Johnson & Johnson announced that the EC approved Tremfya for the treatment of adult patients with moderately to severely active ulcerative colitis.

    In March 2025, Johnson & Johnson announced that the FDA approved Tremfya, which is now the first and only IL-23 offering both subcutaneous and intravenous induction options for the treatment of adults with moderately to severely active Crohn’s disease.

    aficamten In May 2025, Cytokinetics announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application for aficamten to December 26, 2025. The FDA notified Cytokinetics that additional time is required to conduct a full review of the company’s proposed Risk Evaluation and Mitigation Strategy (REMS). No additional clinical data or studies have been requested of Cytokinetics by the FDA.
    Cobenfy In April 2025, Bristol Myers Squibb announced that topline results from the Phase 3 ARISE trial evaluating Cobenfy as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia did not reach the threshold for a statistically significant difference compared to placebo with an atypical antipsychotic for the primary endpoint of the change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score.
    Trodelvy In April 2025, Gilead announced positive topline results from the Phase 3 Ascent-04/Keynote-D19 study, demonstrating that Trodelvy plus Keytruda significantly improved progression-free survival (“PFS”) compared to Keytruda and chemotherapy in patients with previously untreated PD-L1+ metastatic triple-negative breast cancer. Overall survival (“OS”), a key secondary endpoint, was not mature at the time of the PFS primary analysis. However, there was an early trend in improvement for OS with Trodelvy plus Keytruda. Gilead will continue to monitor OS outcomes, with ongoing patient follow-up and further analyses.
    trontinemab In April 2025, Roche announced that new trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase 1b/2a Brainshuttle AD study. Roche expects to initiate a Phase 3 program for trontinemab later this year.
    ecopipam In February 2025, Emalex announced positive Phase 3 results for ecopipam in patients with Tourette syndrome. The study showed statistical significance between ecopipam and placebo for both the primary efficacy endpoint in pediatrics and the secondary efficacy endpoint in pediatrics and adults. Emalex will meet with the FDA and other global health authorities to discuss submission later this year of a New Drug Application (“NDA”).
    Spinraza In January 2025, Biogen announced that the FDA accepted the supplemental NDA and the European Medicines Agency validated the application for a higher dose regimen of Spinraza for spinal muscular atrophy.
    TEV-‘749 In January 2025, Teva announced that TEV-’749 (olanzapine LAI) achieved Phase 3 targeted injections without PDSS (post-injection delirium/sedation syndrome), and the full safety presentation is expected in the second quarter of 2025.


    2025 Financial Outlook

    Royalty Pharma has provided guidance for full year 2025, excluding new transactions and borrowings announced after the date of this release, as follows:

      Provided May 8th, 2025 Previous
    Portfolio Receipts $2,975 million to $3,125 million
    (Growth of ~+6% to 12% year/year)
    $2,900 million to $3,050 million
    (Growth of ~+4% to 9% year/year)
    Payments for operating and professional costs Approximately 10% of Portfolio Receipts Approximately 10% of Portfolio Receipts
    Interest paid $260 million $260 million

    The above Portfolio Receipts guidance represents expected growth of 6% to 12% in 2025. Royalty Pharma’s full year 2025 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2025.

    2025 guidance for payments for operating and professional costs and interest paid does not reflect the impact of the internalization transaction announced on January 10, 2025 and will be updated following the closing of the internalization transaction, which is expected in the second quarter of 2025.

    Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and is anticipated to be approximately $260 million in 2025. Interest paid in the third quarter of 2025 is anticipated to be $119 million. De minimis amounts are anticipated in the second and fourth quarter of 2025. These projections assume no additional debt financing in 2025, including no drawdown on the revolving credit facility. In the first quarter of 2025, Royalty Pharma collected interest of $12 million on its cash and cash equivalents, which partially offset interest paid.

    Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.

    Financial Results Call

    Royalty Pharma will host a conference call and simultaneous webcast to discuss its first quarter 2025 results today at 8:30 a.m., Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.

    About Royalty Pharma plc

    Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates.

    Forward-Looking Statements

    The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

    This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
    Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

    For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

    Portfolio Receipts

    Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that is deployed to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.

    Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy.

    Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests – Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.

    Use of Non-GAAP Measures

    Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.

    The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.

    Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.

    The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.

    Royalty Pharma Investor Relations and Communications

    +1 (212) 883-6772
    ir@royaltypharma.com

     
    Royalty Pharma plc
    Condensed Consolidated Statements of Operations (unaudited)
    Table 1
     
      Three Months Ended March 31,
    ($ in millions) 2025   2024  
    Income and other revenues    
    Income from financial royalty assets 539   542  
    Other royalty income and revenues 29   26  
    Total income and other revenues 568   568  
    Operating (income)/expense    
    Provision for changes in expected cash flows from financial royalty assets (127)   584  
    Research and development funding expense 51   1  
    General and administrative expenses 111   58  
    Total operating expense, net 34   642  
    Operating income/(loss) 534   (74)  
    Other (income)/expense    
    Equity in (earnings)/losses of equity method investees (6)   14  
    Interest expense 65   44  
    Other expense/(income), net 42   (128)  
    Total other expense/(income), net 101   (70)  
    Consolidated net income/(loss) before tax 433   (4)  
    Income tax expense —   —  
    Consolidated net income/(loss) 433   (4)  
    Net income/(loss) attributable to non-controlling interests 195   (9)  
    Net income attributable to Royalty Pharma plc 238   5  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    Selected Balance Sheet Data (unaudited)
    Table 2
     
    ($ in millions) As of March 31, 2025 As of December 31, 2024
    Cash and cash equivalents 1,088 929
    Total current and non-current financial royalty assets, net 15,749 15,911
    Total assets 17,608 18,223
    Current portion of long-term debt 999 998
    Long-term debt, net of current portion 6,619 6,615
    Total liabilities 7,820 7,880
    Total shareholders’ equity 9,789 10,342

     

     
    Royalty Pharma plc
    Condensed Consolidated Statements of Cash Flows (unaudited)
    Table 3
     
       
      Three Months Ended March 31,
    ($ in millions) 2025   2024  
    Cash flows from operating activities:    
    Cash collections from financial royalty assets 830   745  
    Cash collections from intangible royalty assets 0   14  
    Other royalty cash collections 32   26  
    Distributions from equity method investees 13   13  
    Interest received 12   6  
    Development-stage funding payments (51)   (1)  
    Payments for operating and professional costs (102)   (61)  
    Interest paid (139)   (79)  
    Net cash provided by operating activities 596   665  
    Cash flows from investing activities:    
    Distributions from equity method investees 36   5  
    Investments in equity method investees —   (7)  
    Purchases of equity securities (4)   —  
    Proceeds from available for sale debt securities 13   1  
    Proceeds from sales of available for sale debt securities 511   —  
    Acquisitions of financial royalty assets (1)   (86)  
    Milestone payments (50)   —  
    Net cash provided by/(used in) investing activities 504   (87)  
    Cash flows from financing activities:    
    Distributions to legacy non-controlling interests – Portfolio Receipts (85)   (88)  
    Distributions to continuing non-controlling interests (54)   (32)  
    Dividends to shareholders (95)   (94)  
    Repurchases of Class A ordinary shares (709)   —  
    Contributions from legacy non-controlling interests – R&D 0   0  
    Contributions from non-controlling interests – other 1   1  
    Net cash used in financing activities (941)   (212)  
    Net change in cash and cash equivalents 159   366  
    Cash and cash equivalents, beginning of period 929   477  
    Cash and cash equivalents, end of period 1,088   843  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    GAAP to Non-GAAP Reconciliation (unaudited)
    Table 4
     
      Three Months Ended March 31,
    ($ in millions) 2025   2024  
    Net cash provided by operating activities (GAAP) 596   665  
    Adjustments:    
    Proceeds from available for sale debt securities(6) 13   1  
    Distributions from equity method investees(6) 36   5  
    Interest paid, net(6) 127   73  
    Development-stage funding payments 51   1  
    Distributions to legacy non-controlling interests – Portfolio Receipts(6) (85)   (88)  
    Adjusted EBITDA (non-GAAP) 738   656  
    Interest paid, net(6) (127)   (73)  
    Portfolio Cash Flow (non-GAAP) 611   584  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    Description of Approved Indications for Select Portfolio Therapies
    Table 5
     
    Cystic fibrosis franchise Cystic fibrosis
    Trelegy Chronic obstructive pulmonary disease and asthma
    Tysabri Relapsing forms of multiple sclerosis
    Evrysdi Spinal muscular atrophy
    Xtandi Prostate cancer
    Imbruvica Hematological malignancies and chronic graft versus host disease
    Promacta Chronic immune thrombocytopenia purpura and aplastic anemia
    Tremfya Plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease
    Cabometyx/Cometriq Kidney, liver and thyroid cancer
    Spinraza Spinal muscular atrophy
    Trodelvy Breast and bladder cancer
    Erleada Prostate cancer


    Notes

    (1)   Portfolio Receipts is a key performance metric that represents our ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that Royalty Pharma can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma (“Royalty Receipts”). Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy.

    Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests – Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.

    (2)   Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4.

    (3)   Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments.

    (4)   Capital Deployment is calculated as the summation of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments less Contributions from legacy non-controlling interests – R&D.

    (5)   Other products primarily include Royalty Receipts on the following products: Cimzia, Crysvita, Emgality, Entyvio, Farxiga/Onglyza, IDHIFA, Nesina, Nurtec ODT, Orladeyo, Rytelo, Soliqua, Voranigo and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP condensed consolidated statements of cash flows.

    (6)   The table below shows the line item for each adjustment and the direct location for such line item on the GAAP condensed consolidated statements of cash flows.

    Reconciling Adjustment Statements of Cash Flows Classification
    Interest paid, net Operating activities (Interest paid less Interest received)
    Distributions from equity method investees Investing activities
    Proceeds from available for sale debt securities Investing activities
    Distributions to legacy non-controlling interests – Portfolio Receipts Financing activities
       

    (7)   The total transaction value of approximately $1.1 billion is based on the closing price of Royalty Pharma plc common stock of $26.20 on January 8, 2025.

    (8)   Consists of $200 million in cash less the amount of the management fees paid to the Manager from January 1, 2025 through the closing of the transaction.

    The MIL Network –

    May 8, 2025
←Previous Page
1 … 822 823 824 825 826 … 2,041
Next Page→
NewzIntel.com

NewzIntel.com

MIL Open Source Intelligence

  • Blog
  • About
  • FAQs
  • Authors
  • Events
  • Shop
  • Patterns
  • Themes

Twenty Twenty-Five

Designed with WordPress